
==== Front
Cell Mol Life Sci
Cell Mol Life Sci
Cellular and Molecular Life Sciences: CMLS
1420-682X
1420-9071
Springer International Publishing Cham

39136782
5389
10.1007/s00018-024-05389-8
Original Article
Novel CDKL5 targets identified in human iPSC-derived neurons
Massey Sean 1
Ang Ching-Seng 2
Davidson Nadia M. 34
Quigley Anita 5678
Rollo Ben 9
Harris Alexander R. 10
Kapsa Robert M. I. 5678
Christodoulou John 131112
http://orcid.org/0000-0002-6768-3665
Van Bergen Nicole J. N.van@unimelb.edu.au

1313
1 grid.1058.c 0000 0000 9442 535X Brain and Mitochondrial Research Group, Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, VIC 3052 Australia
2 https://ror.org/01ej9dk98 grid.1008.9 0000 0001 2179 088X The Bio21 Institute of Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC Australia
3 grid.416107.5 0000 0004 0614 0346 Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, 3052 Australia
4 https://ror.org/01b6kha49 grid.1042.7 0000 0004 0432 4889 Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052 Australia
5 https://ror.org/04ttjf776 grid.1017.7 0000 0001 2163 3550 Electrical and Biomedical Engineering, School of Engineering, RMIT University, Melbourne, VIC Australia
6 grid.413105.2 0000 0000 8606 2560 Aikenhead Centre for Medical Discovery, St Vincent’s Hospital Melbourne, Fitzroy, Melbourne, VIC 3065 Australia
7 grid.413105.2 0000 0000 8606 2560 Centre for Clinical Neurosciences and Neurological Research, St. Vincent’s Hospital Melbourne, Fitzroy, Melbourne, VIC 3065 Australia
8 https://ror.org/01ej9dk98 grid.1008.9 0000 0001 2179 088X Department of Medicine, St Vincent’s Hospital Melbourne, The University of Melbourne, Fitzroy, Melbourne, VIC 3065 Australia
9 https://ror.org/02bfwt286 grid.1002.3 0000 0004 1936 7857 Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia
10 https://ror.org/01ej9dk98 grid.1008.9 0000 0001 2179 088X Department of Biomedical Engineering, University of Melbourne, Melbourne, 3010 Australia
11 grid.416107.5 0000 0004 0614 0346 Victorian Clinical Genetics Services, Royal Children’s Hospital, Melbourne, VIC 3052 Australia
12 https://ror.org/0384j8v12 grid.1013.3 0000 0004 1936 834X Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, NSW Australia
13 https://ror.org/01ej9dk98 grid.1008.9 0000 0001 2179 088X Department of Paediatrics, University of Melbourne, c/o MCRI, 50 Flemington Road, Parkville, VIC 3052 Australia
13 8 2024
13 8 2024
12 2024
81 1 34726 3 2024
1 7 2024
31 7 2024
© The Author(s) 2024, corrected publicaiton 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
CDKL5 Deficiency Disorder (CDD) is a debilitating epileptic encephalopathy disorder affecting young children with no effective treatments. CDD is caused by pathogenic variants in Cyclin-Dependent Kinase-Like 5 (CDKL5), a protein kinase that regulates key phosphorylation events in neurons. For therapeutic intervention, it is essential to understand molecular pathways and phosphorylation targets of CDKL5. Using an unbiased phosphoproteomic approach we identified novel targets of CDKL5, including GTF2I, PPP1R35, GATAD2A and ZNF219 in human iPSC-derived neuronal cells. The phosphoserine residue in the target proteins lies in the CDKL5 consensus motif. We validated direct phosphorylation of GTF2I and PPP1R35 by CDKL5 using complementary approaches. GTF2I controls axon guidance, cell cycle and neurodevelopment by regulating expression of neuronal genes. PPP1R35 is critical for centriole elongation and cilia morphology, processes that are impaired in CDD. PPP1R35 interacts with CEP131, a known CDKL5 phospho-target. GATAD2A and ZNF219 belong to the Nucleosome Remodelling Deacetylase (NuRD) complex, which regulates neuronal activity-dependent genes and synaptic connectivity. In-depth knowledge of molecular pathways regulated by CDKL5 will allow a better understanding of druggable disease pathways to fast-track therapeutic development.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00018-024-05389-8.

Keywords

CDKL5 deficiency disorder
Phosphorylation
Kinase
Neurodevelopmental disorder
Phosphoproteomics
GTF2I
PPP1R35
http://dx.doi.org/10.13039/501100004752 State Government of Victoria Operational Infrastructure Support Program Van Bergen Nicole J. Foundation for Children 2018-16 Van Bergen Nicole J. http://dx.doi.org/10.13039/100014555 Murdoch Children's Research Institute Strategic Pilot Project in Stem Cell Genomic Medicine Research Grant Near Miss grant Strategic Pilot Project in Stem Cell Genomics Medicine Van Bergen Nicole J. Orphan Disease Center of the University of Pennsylvania MDBR-20-106-CDKL5 Van Bergen Nicole J. Loulou FoundationCDKL5 Forum Junior Fellowship Massey Sean Medical Research Future Funds (MRFF) Stem Cell Therapies MissionMRF2007465 Van Bergen Nicole J. http://dx.doi.org/10.13039/100012789 Veski Near Miss Pilot Award Van Bergen Nicole J. http://dx.doi.org/10.13039/100014607 Royal Children's Hospital Foundation The Chair in Genomic Medicine Christodoulou John Stafford Fox Medical Research FoundationPhenomics Australia Novo Nordisk Foundation reNEW Center for Stem Cell Medicine NNF21CC0073729 Van Bergen Nicole J. National Collaborative Research Infrastructure Strategy University of MelbourneOpen Access funding enabled and organized by CAUL and its Member Institutions

issue-copyright-statement© Springer Nature Switzerland AG 2024
==== Body
pmcIntroduction

The underlying disease pathogenesis of many neurological disorders is a consequence of impairments of kinase function [1]. Understanding how disrupted phosphorylation affects signalling networks that cause abnormal neuronal development and function remains a major challenge in neurobiology. CDKL5 Deficiency Disorder (CDD) is a brain disorder of young children which affects around 1:40,000 live births [2]. CDD is an X-linked disorder caused primarily by de novo pathogenic variants in the Cyclin-Dependent Kinase-Like 5 (CDKL5) gene [3, 4]. Individuals with CDD suffer infantile-onset, drug-resistant seizures, severe neurodevelopmental impairment and profound lifelong disability [5]. CDD shares many clinical features with Rett Syndrome (RTT; caused by mutations in MeCP2) but is recognised as a distinct clinical disorder [6]. Both conditions carry an equivalent health burden of being quadriplegic [7], resulting in four times the annual hospital costs over that of individuals from the general population.

Cyclin-Dependent Kinase-Like 5 (CDKL5) is a protein kinase which modulates key phosphorylation events [8, 9], and is critical for the proper development and maturation of the brain [10, 11]. CDKL5 expression is most abundant in the forebrain; cerebral cortex, hippocampus, striatum and olfactory bulb [12, 13]. At the cellular level, CDKL5 is present in both glutamatergic and GABAergic neurons, with no expression detected in glial cells [14, 15], and its expression increases during neuronal maturation [16, 17]. CDKL5 is located in neuronal growth cones and regulates actin dynamics, synaptic vesicle endocytosis, excitatory synaptic stability, neurite outgrowth and dendritic spine development [16, 18, 19]. Conversely, a lack of CDKL5 expression disrupts dendritic branching and neuronal circuit connectivity [12, 16, 20, 21]. CDKL5 phosphorylates serine or threonine residues in the motif of amino acids RPX(Sp/Tp)[A/G/P] on the target protein [8, 9]. CDKL5 translocates between the nucleus and cytoplasm to phosphorylate specific target proteins in each compartment, thereby regulating their activity. The large C-terminal region of CDKL5 is vital for nuclear-cytoplasmic translocation [22, 23] and is postulated to impart kinase specificity.

With the recent identification of the consensus recognition site for CDKL5, unbiased phosphoproteomics studies have provided greater power in revealing important targets of CDKL5 [8, 9] than prior single-protein targeted investigations [16, 19, 24–26]. However, studies to identify CDKL5 targets have used either a non-neuronal U2O2 bone osteosarcoma cell line [9] or Cdkl5 knockout mouse brain lysates (a mixed population of glia, astrocytes and neurons [8]). These studies revealed that CDKL5 regulates microtubule dynamics and assembly, polarity, cell signalling and cilial regulation by controlling phosphorylation of several microtubule proteins that are critical for correct neuronal architecture. In the nuclear compartment, CDKL5 phosphorylates transcriptional regulators, DNA damage repair proteins and pre-mRNA splicing factors (reviewed by [27]). Despite these advances in CDKL5 target identification, analysis of CDKL5 targets in affected human brain neurons has not yet been attempted. CDD patient-derived neurons differentiated from induced pluripotent stem cells (iPSCs) provide a valuable alternative approach to identification of new CDKL5 targets since the samples are derived from the affected cell type, human brain neurons. Here, we discovered new targets of CDKL5 identified using an unbiased phosphoproteomics study in an iPSC-derived human brain neuronal model from a CDD patient. We used our existing CDD model which utilised a patient-derived male iPSC line [CDKL5; c.175C > T, p.(Arg59*)] and CRISPR-Cas9 gene-corrected isogenic controls (genetically matched) [28]. We generated bona fide human iPSC-derived cortical neurons by dual-SMAD inhibition [29–32], which we previously demonstrated recapitulate many features of CDD, including impaired neurite outgrowth and reduced phosphorylation of EB2 [28], which is a direct phosphorylation target of CDKL5 [8, 9, 16]. We reveal perturbed phosphorylation pathways in patient-derived neurons that are critical for neuronal function. Such knowledge may identify CDKL5 brain-specific signalling and regulatory pathways underpinning CDKL5 function. It is important to note that the discovery of CDKL5 targets in human neuronal cells is a pre-requisite to identify new targeted treatments for CDD.

Materials and methods

Patients and cell lines

iPSC from a male patient with the CDKL5 pathogenic variant c.175C > T [p.(Arg59*)] [6] and isogenic controls were generated and previously characterised [28]. iPSC were differentiated into neurons for 35 days of maturation as previously described [28] for RNAseq and phosphoproteomics.

RNAseq and quantitative PCR analysis

RNA was isolated using a commercially available kit (Qiagen RNeasy® kit), quality-control checked (Qubit and TapeStation) and sequenced at the Victorian Clinical Genetics Services (Illumina TruSeq stranded mRNA library) on the NextSeq 500 with paired-end 75 bp reads and approximately 30 million fragments per sample. Fastqc was run on each fastq file, reads trimmed then aligned to the human reference genome (hg38) using STAR version 2.5.2[33] in two pass mode. Duplicate reads were removed using Picard Tools MarkDuplicates version 2.0.1 [34]. Aligned reads were summarised to genecode version 20 [35] gene-level counts using featureCounts v1.5.0 [36]. The genotype of samples was confirmed in IGV [37]. One CDKL5 p.(Arg59*) neuron sample failed genotyping QC and was excluded. Count data was analysed in R (Version 3.4.0) using edgeR glmLRT [38] method (version 3.18.1) to assess gene expression changes. Genes with a false discovery rate (FDR) of < 0.05 and a fold-change (FC) of > 2 were considered significant (Supplemental Table 1).

cDNA was synthesized (GoScript™ Reverse Transcription random hexamers master mix, Promega) and quantitative reverse-transcription PCR reactions were conducted with custom primers (Supplemental Table 2) and AccuPower® 2X Greenstar™ qPCR Master Mix (Bioneer Pacific) on a Roche LightCycler 480 II.

Phosphopeptide enrichment of neuronal lysates

Proteins were rapidly extracted from neurons in chilled RIPA buffer [25 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.5% sodium dodecyl sulfate (SDS), 1 mM ethylenediaminetetraacetic acid (EDTA)] containing protease and phosphatase inhibitors (protease and phosphatase inhibitor mini tablets, EDTA-free, Pierce), sonicated, protein concentration estimated (BCA kit, Pierce) then stored at −80 °C. 1 mg of proteins were precipitated overnight at − 20 °C, using 5 × volume ice cold acetone. The following day the samples were centrifuged at 15,282×g for 10 min, pellet rinsed with ice cold acetone and centrifuged again. The pellet was solubilized in 8 M urea in 50 mM tetraethylammonium bromide (TEAB) and incubated for 30 min at 37 °C. 10 mM tris(2-carboxyethyl)phosphine (TCEP) and 55 mM iodoacetamide was added and incubated at 37 °C for 45 min. Samples were then diluted to 1 M urea with 25 mM TEAB and digested overnight in the dark at 37 °C with sequencing grade modified trypsin (Pierce, #90057) at 1:50 protein:enzyme (20 µg of trypsin per 1 mg sample). Samples were acidified to 1% (v/v) trifluoroacetic acid (TFA). Oasis HLB 60 mg cartridges were washed with 80% acetonitrile (ACN) containing 0.1% TFA, followed two washes with 0.1% TFA. Proteins were loaded onto cartridges and washed with 0.1% TFA twice then eluted with 80% ACN containing 0.1% TFA. A final BCA assay was performed for equal sample loading and 20 µg of sample was freeze-dried for total proteomics. These samples were then resuspended in a buffer containing 2% ACN, 0.05% TFA before LC–MS/MS analysis. The remaining ~ 980 µg of sample was freeze-dried and stored at −80 °C until phosphopeptide enrichment.

For phosphopeptide enrichment, TiO beads (Titansphere Phos-TiO beads, GL Sciences inc; ratio of 6:1 TiO:peptides) were washed with 50% ACN, 5% TFA and then incubated for 10 min with 2 M lactic acid in 5% TFA (washing buffer), 50% ACN (loading buffer). TiO beads in loading buffer were added to the freeze-dried phosphoproteomic peptide pellet samples and incubated for 1 h with shaking at high speed. The sample was briefly centrifuged, then loaded onto C8 zip tips (200 µl volume) and eluant passed over tip again to maximise binding.

The phosphopeptides were washed twice with loading buffer then three times with washing buffer. The phosphopeptides were eluted off with three elutions of 30 µl of elution buffer (1% (v/v) NH4OH, pH 11), followed by a 10 µl elution with 30% ACN. Elutions were pooled and acidified with 1 µl of formic acid per 10 µl eluent then freeze-dried and stored at −80 °C. The phosphopeptides were randomized and resuspended in 2% ACN, 0.05% TFA just before LC–MS/MS analysis.

Mass spectrometry (MS) analyses of neuronal lysates

Samples were analysed by nanoESI-LC–MS/MS using an Orbitrap Exploris 480 mass spectrometer (Thermo Scientific) and a nanoflow reversed-phase-HPLC (Ultimate 3000 RSLC, Dionex). The LC system was equipped with an Acclaim Pepmap nano-trap column (Dinoex-C18, 100 Å, 75 µm × 2 cm) and Acclaim Pepmap RSLC analytical column (Dinoex-C18, 100 Å, 75 µm × 50 cm). The tryptic peptides were injected (1 mg) to the enrichment column at an isocratic flow of 5 µL/min of 2% v/v ACN containing 0.1% v/v formic acid for 5 min applied before the enrichment column was switched in-line with the analytical column. The eluents were 5% DMSO in 0.1% v/v formic acid (solvent A) and 5% DMSO in 100% v/v ACN and 0.1% v/v formic acid (solvent B). The flow gradient was (1) 0–6 min at 3% B, (2) 6–95 min, 3–22% B, (3) 95–105 min 22–40% B, (4) 105–110 min, 40–80% B, (5) 110–115 min, 80–80% B, (6) 115–117 min, 80–3% and equilibrated at 3% B for 10 min before the next sample injection. All spectra were acquired in positive ionization mode with full scan MS acquired from m/z 300–1600 in FT mode at mass resolving power of 120 000, after accumulating to AGC target value of 3.0E6, with maximum accumulation time of 25 ms. The RunStart EASY-IC lock internal lockmass was used. Data-dependent HCD MS/MS of charge states > 1 was performed using a 3 s scan method, at a normalized AGC target of 100%, automatic injection, a normalized collision energy of 30%, and spectra acquired at resolving power of 15 000. Dynamic exclusion was used for 20 s.

Raw files were processed with MaxQuant (version 1.6.17.0) [39] against Homo sapiens proteome (SwissProt, downloaded April 2019) using default search parameters (Trypsin as cleavage enzyme, cysteine carbamidomethyl as fixed modification and methionine oxidation, serine, threonine and tyrosine phosphorylation as variable modifications) and match between run option selected, with a maximum false discovery rate (FDR) of < 0.01.

Phosphoproteomics analysis

Phosphoproteomic data was analysed with Perseus (version 1.6.1.14 and 1.6.5.0). Contaminants and reverse peptides were removed and peptides with a phosphate localization probability higher than 0.75 were kept. Phosphopeptide intensities were log2 transformed, annotated and phosphopeptides with valid values (in at least three samples in at least one group) were kept for statistical analysis. Intensities were normalized by subtracting the median and imputed missing values from normal distribution (0.3 width, 1.8 down shift). Significant hits were defined using Perseus Software; Two-sided Student’s t-test, truncated by permutation-based FDR threshold of 0.05 (250 randomizations) and S0 factor of 0.1. Gene Ontology SLIM biological process [40, 41] was used to classify protein function. STRING [42, 43] analysis with high confidence (0.900) examine protein networks. Phosphomotif enrichment was analysed with the motif enrichment programs MeMe Suite [44] and MoMo [45]. PhosphositePlus [46] and the Kinase Library [47] were used for kinase–substrate pair prediction [48]. Phosphomatics (https://phosphomatics.com/) was used for kinase-substrate enrichment (KSEA; with a p-value threshold of 0.05, Networkin score threshold of 5, and a M-threshold of 5) and to generate kinase-substrate network interactions.

DNA constructs

Plasmids from Genscript (GATAD2A clone OHu17401, ZNF219 clone OHu06145, and PPP1R35 clone OHu31026) were cloned into the pcDNA5D FRT/TO plasmid with a C-terminal 3FLAG tag. GTF2I was expressed from the pEBG plasmid with N-terminal GST tag from Addgene (plasmid #22156) because endogenous GTF2I co-precipitated with GTF2I-FLAG during FLAG pulldown assay trials. Site-directed mutagenesis was used to mutate serine into alanine (QuikChange Lightning Site-Directed Mutagenesis Kit, Agilent). Full-length untagged CDKL5 (wild-type and CDKL5 kinase‐dead K42R) were obtained from MRC Protein Phosphorylation and Ubiquitination Unit (clones 55082 and 53500). Primer sequences are available in Supplemental Table 2.

Cell transfections, whole-cell extract preparation and Western blotting

HEK293T cells were cultured in DMEM (Thermo Fisher) + 10% FCS and 1 × penicillin–streptomycin and were seeded at 1.2 × 106 cells per 100 mm plate then transfected 24 h later using lipofectamine 2000 (Thermo Fisher) with a total of 3 µg of plasmid (1.5 µg + 1.5 µg for plasmid co-transfections) for 24 h. On ice, cells were washed twice in PBS then lysed in lysis buffer (50 mM Tris–HCl (pH 7.4) buffer containing 0.27 M sucrose, 150 mM NaCl, 1% (v/v) Triton X-100, 0.5% (v/v) Nonidet NP-40 and 0.1% (v/v) 2-mercaptoethanol) supplemented with a protease and phosphatase inhibitor cocktail (protease/phosphatase inhibitor cocktail #5872, Cell Signaling Technologies or Pierce protease and phosphatase inhibitor mini tablets) and benzonase (Novagen, 50U/ml) with scraping then cleared by centrifugation at 12,000g for 20 min. 20 µg of protein was mixed with SDS–PAGE sample buffer containing 5% (v/v) 2-mercaptoethanol before boiling at 95 °C. Samples were resolved by 4–12% Tris–glycine SDS–PAGE gradient gels (Biorad) and transferred to Amersham Hybond 0.45 μm PVDF membrane for 90 min at 100 V. The membrane was blocked in 5% (w/v) non-fat dry milk in TBS–Tween-20 (0.2% v/v) for either 1 h at RT or 4 °C overnight with diluted primary antibodies. The membrane was washed three times in TBS–Tween-20 (0.1%(v/v)), incubated with secondary antibodies in blocking buffer for 1 h, then washed three times before adding Biorad Clarity Chemiluminescent Substrate (Biorad) and capturing ECL signal on Biorad ChemiDoc MP Imaging System imager or Amersham ECL Hyperfilm. See Supplemental Table 3 for antibody information.

Conjugation of antibody to immunoprecipitation (IP) beads

For IP, antibodies were cross-linked to IP beads and scaled according to needs. 20 µl of a 50% bead slurry (10µL settled beads, Protein G Agarose beads, Cell Signaling Technologies) were washed twice with PBS followed by centrifugation at 3341×g for 1 min. Dilution buffer (1 mg/mL BSA in PBS) was added at 1:1 ratio buffer:beads, mixed by rotation for 10 min, centrifuged, then wash buffer removed. Antibody (1 µg per 10 µl settled beads, either anti-FLAG or anti-GST) in dilution buffer was added to beads and incubated for 1 h at 4 °C. Beads were washed in dilution buffer followed by PBS wash at 1:1 ratio. Dimethyl pimelimidate (DMP, pH 8–9, 13 mg/ml) was freshly prepared then added to beads at 1:1 ratio and incubated with rotation at RT for 30 min then removed. Beads were washed with 10 volumes of 0.2 M triethanolamine (TEA) in PBS. The DMP and TEA steps were repeated twice. The reaction was then quenched by the addition of 50 mM ethanolamine in PBS at 1:1 ratio for 5 min, and repeated. The beads were washed with 10 volumes of PBS. Excess unlinked antibody was removed with 1 M glycine, pH 3 at 1:1 ratio and repeated. The beads were washed in cell lysis buffer three times prior to IP.

IP for western blot and MS

For IP, HEK293T whole-cell extract was prepared and 400 µg of cell lysate was added to 20 µl of settled conjugated beads in Eppendorf LoBind tubes and incubated for 2 h at 4 °C with rotation. Beads were washed three times with 10 × volume of lysis buffer, followed by three washes of 10 ×, 20 × then 40 × volume of ice-cold PBS. After each wash beads were centrifuged at 3341×g for 1 min. The sample was split equally for western blot and MS.

IP samples for western blot were eluted off the 10 µl of beads by the addition of 70 µl of 3 × SDS-PAGE loading buffer (187.5 mM Tris–HCl pH 6.8, 15% SDS, 30% glycerol, 0.03% bromophenol blue and 5% 2-mercaptoethanol) and incubation at 95 °C for 5 min. 20 µl of eluant was loaded onto each gel and separated by SDS-PAGE as described above. Membranes were probed for either FLAG or GST tag, the target protein or for phosphorylated target using the Phospho-MAPK/CDK substrates antibody.

IP samples for MS were eluted off 10 µl of beads by sequential addition of 25 μL of 100 mM TEAB, 25 μL neat TFE, 0.5 μL of 10% formic acid then 2.5 μL of 200 mM TCEP then heated at 60 °C for 1 h and centrifuged at 6000 rpm. The supernatant was moved to a new tube and 10 µl of fresh 200 mM iodoacetamide (IAM, Sigma, A3221, dissolved in 25 mM TEAB) was added, vortexed then incubated at RT for 45 min in the dark. Subsequently 2.5 µl of 200 mM TCEP was added and incubated for 30 min in the dark. 300 µl of water diluted the sample then 100 µl of 100 mM TEAB added, and pH adjusted to 7.5–8.0 by the incremental addition of 0.5 M NaOH and pH measured with litmus paper. Sequencing grade modified trypsin (Pierce, #90057) was diluted to 0.1 µg/µl in 25 mM TEAB and 5 µl was added and incubated at 37 °C overnight. Then 2 µl of neat formic acid was added, centrifuged at 13,000g for 10 min, supernatant transferred to a new LoBind tube, freeze-dried overnight then stored at −80 °C until MS analysis. Just prior to loading, the freeze-dried pellet was resuspended in 20 µl of 2% ACN/0.05% TFA, vortexed, incubated in a sonicating water bath for 3 min, centrifuged at 13,000 g for 10 min then repeated twice. 10 µl was then loaded on for MS analysis.

For the IP experiment the MS was operated in a targeted data-dependent mode with a targeted inclusion list containing predicted phosphopeptides from GTF2I, PPP1R35, GATAD2A and ZNF219. The inclusion list consisted of mass/charge (m/z) and charge (z) of tryptic peptides predicted from an in-silico digest of target proteins using Skyline software [49] and peptides previously observed in public data depositories through PeptideAtlas [50] and the present study. The nanoLC separation was identical to the above method and an Orbitrap Eclipse mass spectrometer was used. Full MS1 spectra were acquired in positive mode, 120,000 resolution, AGC target of 4e5 and maximum IT time of 50 ms. A loop count of 10 on the most intense targeted peptide were isolated for MS/MS. The isolation window was set at 1.2 m/z and precursors fragmented using normalized collision energy of 30. Resolution was at 15,000 resolution, AGC target at 2e5 and maximum IT time of 110 ms. Dynamic exclusion was set to 30 s. The system performed a dependent scan on the most intense ion if no targets were found.

Synthesis of custom phospho-antibodies

Rabbit polyclonal phosphospecific antibodies were raised against phosphorylated (Sp) peptides by Covalab by triple immunisation of New Zealand White rabbits with two phosphopeptides and one peptide control. For GTF2I Ser674 two phosphopeptides CLQSPKRPR[Sp]PGSNS and CKRPR[Sp]PGS and one peptide control CLQSPKRPRSPGSNS were used. For PPP1R35 Ser52 two phosphopeptides CDLSLSPRPD[Sp]PQPRH and CSPRPD[Sp]PQP and one peptide control DLSLSPRPDSPQPRH were used. Serum samples were tested pre-immunisation and at day 53 during production for reactivity against full-length protein expressed in HEK293T cells. Final bleeds at day 72 were affinity purified by Covalab. The serum was loaded onto a column with control peptide coupled to agarose beads, retaining unmodified peptide‐specific antibodies. The flow‐through was loaded onto a column with one of the two modified peptides coupled to agarose beads, retaining modified peptide‐specific antibodies. After elution, the eluate was assayed at Covalab using ELISA against both phosphopeptides and peptide control to determine antibody immunoreactivity and specificity for the phospho-modification.

IP for western blot with custom phospho-antibody

For IP, 1 µg of epitope antibody (FLAG or GST) was pre-incubated with 10 µl of settled beads in 1 mg/ml BSA in PBS at 4 °C overnight. Beads were washed twice with PBS and 200 µg of cell lysate was incubated for 2 h at 4 °C with rotation. The beads were washed three times with 10 × volume of lysis buffer, then three washes of 10 ×, 20 × then 40 × volume of ice-cold PBS and centrifuged at 3341×g for 1 min. IP samples for western blot were eluted with 70 µl of 3 × SDS-PAGE loading buffer and incubation at 95 °C for 5 min. 20 µl of eluant was loaded onto each gel, samples separated by SDS-PAGE and transferred to PVDF. Samples were probed for either FLAG or GST tag, the protein being immunoprecipitated or phosphorylated target using custom phospho-antibodies. See Supplemental Table 3 for antibody information.

Statistical analysis

Statistical analyses were carried out using either a two-tailed Student’s t-test or one-way ANOVA corrected for multiple comparisons (GraphPad Prism Software, Version 8, San Diego, CA, USA). Error bars represent the standard error of the mean (± SEM) and a p-value of < 0.05 was considered statistically significant.

Results

Phosphoproteomic screening in CDKL5 human neurons reveals global perturbances to phosphorylation

To identify the phosphoproteomic changes and search for new CDKL5 phosphorylation targets, we used unbiased quantitative LC–MS/MS established for mouse cortical neurons [51, 52] which enabled the identification of new CDKL5 targets in human neurons (Fig. 1A, Supplemental Figure 1, Supplemental Table 4). A total of 4271 unique phosphosites were identified, and 454 phosphosites considered significant (Fig. 1B), of which 290 phospho-sites were enriched in isogenic controls. Most phosphorylation events occurred on serine residues, consistent with reports that CDKL5 deficiency predominantly affects serine phosphorylation [9].Fig. 1 Phosphoproteomic workflow and analysis in CDKL5 human neurons. A Workflow for phosphoproteomic analysis in neurons. Neurons from CDKL5 p.(Arg59*) and CDKL5 isogenic controls were cultured in parallel for phosphoproteomic analysis. Neurons were lysed and protein extracts were subject to trypsin digest, peptides were extracted and phosphopeptides were enriched from each sample using TiO2 chromatography. Peptides were separated on a nano-HPLC and analysed by quantitative MS on an Orbitrap Mass Spectrometer. Data was analysed with MaxQuant software and visualised in Perseus software.

Source data for the Fig. is available in Supplemental Materials and online. B Hierarchical heatmap clustering (z-score normalized) of significantly changed proteins from two-sided students T-test (BH FDR < 0.05, S0 = 0.1; n = 6 CDKL5 isogenic control neurons, n = 3 CDKL5 p.(Arg59*) neurons) between the CDKL5 p.(Arg59*) and CDKL5 isogenic control showing phosphosites identified by phosphoproteomic analysis. Horizontal tree indicates 9 independent samples. Vertical tree indicates the 454 significant phosphosites identified. Phosphorylation proteins were separated into two clusters, and each cluster was interrogated by Gene Ontology (GO) analysis. Two of the proteins clusters showing shared GO clusters were bracketed and individual samples were plotted as profile plots of log2-transformed normalized intensities for phosphoproteins in CDKL5 p.(Arg59*) and CDKL5 isogenic controls

Heatmap and hierarchical clustering data (Fig. 1B, left side), separated significantly changed phosphosites into two clusters (Fig. 1B, right side) and Gene Ontology (GO) biological process analysis revealed protein function in each cluster. Cluster 1, with higher phosphorylation in CDKL5 p.(Arg59*) neurons (Fig. 1B) was enriched for pyrimidine nucleobase catabolic processes, dendrite and synapse organization, cell migration, regulation of microtubule dynamics and organization, and intracellular signal transduction. Cluster 2, representing higher phosphorylation in CDKL5 isogenic control neurons (Fig. 1B), was enriched for mRNA splicing, chromosome organization and DNA metabolic processes. STRING protein cluster grouped phosphorylation events into three major classes; of cytoskeletal protein binding, histone binding and RNA binding (Fig. 2). Cytoskeletal proteins including MAPT, MAP1A, MAP1B, MAP2, NCAM1 and DCX were more highly phosphorylated in CDKL5 p.(Arg59*) neurons. Histone and RNA binding proteins had increased phosphorylation in CDKL5 isogenic controls, including six Serine/Arginine Rich Splicing Factor (SRSF) proteins.Fig. 2 Global phosphoproteomic STRING network analysis in CDKL5 human neurons. STRING analysis (http://www.string-db.org) derived protein–protein interaction networks for phosphoproteins that are differentially regulated in CDKL5 p.(Arg59*) compared to CDKL5 isogenic control neurons. The network nodes represent proteins. Log reporter intensity is from CDKL5 p.(Arg59*)/CDKL5 isogenic control data presented in volcano plot in Fig. 4A, so blue represents higher in CDKL5 p.(Arg59*) and red represents higher in CDKL5 isogenic control. Reporter intensity is indicated by a blue or red circle around the protein name. Interaction score in STRING is set at the highest confidence (0.900), and major gene ontology groups highlighted in the centre of the circle, with cytoskeletal proteins (pink centre), histone-binding proteins (green centre) and RNA binding proteins (yellow centre) indicated

Kinase-Substrate Enrichment Analysis (KSEA) predicted the upstream kinases disrupted in CDKL5 p.(Arg59*) neurons (Fig. 3A). There was enrichment of GSK3α, GSK3β and CDK5 signalling in CDKL5 p.(Arg59*) neurons, whilst in CDKL5 isogenic control neurons there was enrichment of CSNK2A2, CDK1, CDK2, PRKDC, MAPK8 and CLK2 signalling. All of these kinases, including CDKL5 are within the CMGC kinase family (Fig. 3B) and particularly, GSK3A and GSK3B are closely related to CDKL5 in the human kinome phylogenetic tree. Of the 454 significantly altered phosphosites, only 48 sites (~ 10%) had a reported kinase in PhosphoSitePlus (Supplemental Table 5). The kinase-substrate (K–S) relationships were represented in a network diagram (Fig. 3C) which demonstrated disruptions to kinase signalling cascades in CDKL5 p.(Arg59*) neurons.Fig. 3 Kinome profiling and kinase-substrate interaction in CDKL5 neurons. Phosphoproteomic data was analysed in Phosphomatic.com to determine disrupted kinase activity in CDKL5 neurons. A KSEA analysis provides information on signalling cascades that are altered in CDD subsequent to pathogenic variants in CDKL5. KSEA analysis identifies kinases that are associated with phosphorylation sites in a data set that substantially differ in abundance between two treatment groups. The KSEA Z-score assesses the statistical significance of inferred activities, by normalizing the total log-fold change of substrates with the standard deviation of the log-fold changes of all sites in the dataset. Blue bars represent enrichment of the phospho-sites in CDKL5 isogenic control neurons (Z-scores less than 0) and red bars represent enrichment of the phospho-sites in CDKL5 p.(Arg59*) neurons (Z-score greater than 0). B Kinases from KSEA were mapped onto the human kinase map and circles represent enrichment of kinases that phosphorylate phospho-sites from KSEA analysis. Blue circles are higher in CDKL5 isogenic control neurons and red circles are higher in CDKL5 p.(Arg59*) neurons. CDKL5 is indicated in yellow. C The phosphoproteomic network displays specific relationships between the substrates in CDKL5 isogenic controls compared to CDKL5 p.(Arg59*) neurons and known upstream kinases based on data from PhosphoSitePlus and Signor. Network diagrams represent substrates of the active data group as coloured circles (blue is higher in CDKL5 isogenic control and red is higher in CDKL5 p.(Arg59*) neurons) and known upstream kinases as green circles. Colour-coding of substrates represents mean fold-change between the two groups

Enrichment of phosphorylation motif identifies potential new neuronal targets of CDKL5

The most highly enriched phosphomotif in the phosphoproteomic dataset was PxSpP (where ‘X’ is any residue), with a 27-fold enrichment (p-value of 4.60 × 10–6, Supplemental Table 6), followed by SpP with a 26-fold enrichment (p-value of 6.40 × 10–6). The combined enriched motif was RPXSpPXE which corresponds to the CDKL5 consensus phosphomotif RPX(Sp/Tp)[A/G/P] [8, 9]. In our dataset there were 4 protein targets that contained the complete CDKL5 consensus phosphomotif (Fig. 4) with phosphosignal elevated in CDKL5 isogenic control neurons. The four proteins and phosphorylated residue were GATAD2A Ser100, General Transcription factor II-I (GTF2I, also known as TFII-I) Ser674 (Uniprot P78347, or S633 in isoform 2; P78347-2), ZNF219 Ser114 and PPP1R35 Ser52 (Fig. 4B). Ser674 in GTF2I was identified from two different phosphopeptides (Supplemental Table 7). Importantly no phosphopeptides containing the consensus CDKL5 motif were identified elevated in CDKL5 p.(Arg59*) neurons. The phosphorylation motifs were highly conserved (Fig. 4B, Supplemental Figure 2).Fig. 4 Identification of potential specific CDKL5 phosphotargets in CDKL5 human neurons. A Label free quantitative phospho-MS (LFQPMS) of phosphorylated CDKL5 neuronal proteins (left = higher in wild-type), highlighting sites containing the CDKL5 consensus motif. Volcano plot shows significantly changed proteins from Perseus analysis (BH FDR < 0.05, S0 = 0.1; n = 6 CDKL5 isogenic control neurons, n = 3 CDKL5 p.(Arg59*) neurons). B Conservation of phosphorylated sites in proteins containing the CDKL5 motif. C Phosphorylation level of targets in each sample were consistent between replicate samples. Each coloured line represents phosphorylation levels of the four targets identified in volcano plot in Fig. 4A (PPP1R35 in green, GTF2I in blue, GATAD2A in red and ZNF219 in purple)

We identified the predicted kinase at each phosphorylation site in our dataset (Supplemental Table 7) [47]. For GTF2I Ser674, CDKL5 is predicted to be the 6th most likely kinase, for PPP1R35 Ser52, CDKL5 is the 2nd most likely kinase, for GATAD2A Ser100 CDKL5 had a lower Log2 score and ranked as the 14th most likely kinase whilst for ZNF219 Ser114 CDKL5 was the 10th most likely kinase.

PPP1R35 as a new potential CDKL5 phospho-target

To confirm if PPP1R35 is a bona-fide target of CDKL5, we co-expressed either wild-type PPP1R35 (PPP-WT) or PPP1R35 mutant Ser52Ala (SA) protein with either CDKL5 wild-type (CDKL5-WT) or CDKL5 kinase-dead (K42R) protein, enriched protein by IP and determined phosphorylation levels by MS and western blotting, as previously described[9]. We utilised an antibody that recognises phospho-MAPK/CDK substrates with a phospho-motif (PXS*P or S*PXR/K) that would detect proteins containing the CDKL5 motif (Fig. 5A).Fig. 5 Orthogonal validation approach to demonstrate that CDKL5 phosphorylates PPP1R35 at Ser52 in human cells. A HEK293T cells were co-transfected with CDKL5 WT or CDKL5 K42R and PPP1R35 (PPP) WT or PPP1R35 S52A, where serine is converted to an alanine. Cells were then lysed and the target was immunoprecipitated with an antibody against the epitope FLAG tag. Immunoprecipitated proteins were split between quantitative phospho-MS and phospho-western blotting. B Anti‐FLAG immunoprecipitates were probed with Anti-MAPK/CDK -Phospho (top panel), and anti-FLAG (bottom panel). Empty vector (EV) lysates were used as a negative control. Quantification of three independent experiments showed a significant increase in the phosphorylation levels of PPP1R35 WT when co-expressed with CDKL5 WT compared to either empty vector or CDKL5 kinase dead (K42R) mutant. Site-directed mutagenesis (PPP1R35 S52A) did reduce overall phosphorylation levels when comparing PPP1R35 WT to PPP1R35 S52A. Data is representative of 3 independent samples from 3 independent experiments. Data is mean ± SEM. *P < 0.05, **P < 0.01. One-way ANOVA with Dunnett’s multiple comparisons test. C Lysate extract sets from co-transfection experiments were probed with anti-CDKL5 (top panel), anti-FLAG (middle panel) and anti-GAPDH (bottom panel). The expression patterns indicate that the co-transfection experiments were successful. Three independent experiments were completed, and one representative experiment is shown. D Phosphorylation of PPP1R35 WT was higher in HEK293T cells co-transfected with CDKL5 WT compared to co-transfected with CDKL5 K42R or empty vector. Phospho-peptides were quantified using LC–MS/MS intensity of phosphopeptides and was normalised to the label-free quantification of PPP1R35. Data is representative of 10 independent samples from six independent experiments. Data is mean ± SEM. ***P < 0.001. One-way ANOVA with Sidak’s multiple comparisons test. E Phosphopeptide detected from PPP1R35 that is phosphorylated by CDKL5

When CDKL5 WT was co-expressed with PPP1R35 WT, phosphorylation levels were significantly higher than when co-expressed with CDKL5 K42R (Fig. 5B, C). Site-directed mutagenesis which abolished the phosphoserine site of PPP1R35 significantly reduced phosphorylation levels.

We then generated a custom antibody against the PPP1R35 Ser52 site which was tested and validated for specificity to PPP1R35 Ser52 (Supplemental Figures 3, 4B, 5C). This custom phospho-antibody also confirmed that highest phosphorylation occurred when PPP1R35 WT was co-expressed with CDKL5 WT, and phosphorylation was significantly lower when co-expressed with CDKL5 K42R (Supplemental Figure 6).

Quantitative phospho-MS from IP samples above (Supplemental Table 8) demonstrated the highest phosphorylation of PPP1R35 at Ser52 occurred when CDKL5 WT was co-expressed with PPP1R35 WT and was significantly lower when co-expressed with CDKL5 K42R (Fig. 5D). Site-directed mutagenesis (S52A) completely abolished the phospho-signal on PPP1R35 (Supplemental Fig. 7A) even though protein input was similar (Supplemental Fig. 7B and Fig. 5C, α-FLAG lane). The PPP1R35 peptide identified by MS in both neuronal phosphorylation data and IP data (APVPEPGLDLSLSPRPDSPQPR) correctly identified the phosphoserine Ser52 within the CDKL5 motif (Fig. 5E). Together the data provides evidence that CDKL5 directly phosphorylates PPP1R35 at Ser52.

GTF2I as a new potential CDKL5 phospho-target

Using the same co-IP approach as for PPP1R35, we assessed whether CDKL5 directly phosphorylates GTF2I at Ser674. The antibody that detects phospho-MAPK/CDK substrates only produced a faint signal but still revealed the highest phosphorylation level when GTF2I WT was co-expressed with CDKL5 WT (Supplemental Fig. 8). We then generated and validated custom phospho-specific antibody for GTF2I Ser674 (Supplementary Figs. 4A, 5A, and 9). With this antibody we showed highest phosphorylation when GTF2I WT was co-expressed with CDKL5 WT, and phosphorylation levels were significantly lower when co-expressed with CDKL5 K42R (Fig. 6A, B). Quantitative MS only detected phosphorylation events in immunoprecipitated GTF2I WT when co-expressed with CDKL5 WT and phosphorylation was never detected when GTF2I WT was co-expressed with CDKL5 K42R or empty vector control (Fig. 6C, Supplemental Table 9). GTF2I protein input levels were similar for MS analysis (Supplemental Fig. 10B). This evidence supports the conclusion that CDKL5 directly phosphorylates GTF2I at Ser674.Fig. 6 Orthogonal validation approach to demonstrate that CDKL5 phosphorylates GTF2I at Ser674 in human cells. A Quantification of three independent experiments showed a significant difference in the phosphorylation levels in GTF2I when co-expressed with CDKL5 WT compared to either empty vector (EV) or CDKL5 kinase dead (K42R) mutant. Site-directed mutagenesis of GTF2I at Ser674 to Ala (SA) completely abolished phosphorylation levels and was not quantifiable. Data is representative of 5 independent samples from 5 independent experiments. Data is mean ± SEM. *P < 0.05. B Lysate extract sets from co-transfection experiments were probed with anti-CDKL5 (top panel), anti-GTF2I (middle panel) and anti-GAPDH (bottom panel). Five independent experiments were completed and the expression patterns indicate that the co-transfection experiments were successful. Data is mean ± SEM. *P < 0.05. One-way ANOVA with Dunnett’s multiple comparisons test. C Phosphorylation of GTF2I WT was only detected in HEK293T cells co-transfected with CDKL5 WT compared to co-transfected with CDKL5 K42R or empty vector. Phospho-peptides were quantified using LC–MS/MS intensity of phosphopeptides was normalised to the label-free quantification of GTF2I. The phosphorylation event was detected in two of six independent experiments. D Phosphopeptide detected from GTF2I that is phosphorylated by CDKL5

The custom phospho-antibodies generated for both GTF2I and PPP1R35 were not able to detect endogenous phosphorylation of GTF2I or PPP1R35 in neuronal lysates due to high background signal despite multiple attempts (data not shown).

Downstream targets of GTF2I regulation are altered in CDKL5 p.(Arg59*) neurons

GTF2I regulates of a suite of genes primarily in the brain and phosphorylation may modulate transcriptional activity[53, 54]. RNAseq Differential Expression (DE) analysis identified 379 genes significantly downregulated in CDKL5 p.(Arg59*) neurons, and 99 significantly upregulated when compared to CDKL5 isogenic controls (Supplemental Table 1).

We compared the list of DE genes in CDKL5 to previously reported RNAseq datasets of GTF2I-regulated genes. This included data from Gtf2i-knockout mouse brain, brain biopsies from Williams-Beuren Syndrome (WS) patients with a microdeletion including GTF2I, WS iPSC [53, 54] and WS fibroblasts [55]. We identified 20 genes dysregulated in CDKL5 p.(Arg59*) neurons that were also dysregulated in WS brain biopsies and WS iPSC [53–55]. Of these 20 genes, 10 genes were downregulated in both CDKL5 p.(Arg59*) neurons and WS (Supplemental Table 10) and one gene, BEND4 was upregulated in both (Supplemental Fig. 11). Comparison of our DE list to Gtf2I-knockout mouse cortex [54] revealed an additional 3 genes, two of which were similarly downregulated both in the mouse model and in our CDKL5 p.(Arg59*) neurons. Additionally, 2 genes, the gap junction connexin family gene Gjc2 and the claudin family gene Cldn11, were downregulated in the Gtf2I knockout mouse cortex [54]. Although the Gjc2 and Cldn11 genes were unchanged in our CDKL5 neurons, other genes in the gap junction connexin family, GJB7, GJA1 and the claudin family, CLDN1, CLDN4 and CLDN6 were downregulated in CDKL5 p.(Arg59*) neurons (Supplemental Table 10). GTF2I represses BEND4 expression [53] and both our RNAseq (Supplemental Table 10) and qPCR analysis (Supplemental Fig. 11) showed increased BEND4 in CDKL5 p.(Arg59*) neurons. BEND4 protein was not detected in our proteomics dataset [28]. There was no change in GTF2I transcript or protein abundance [28] implying that any changes to GTF2I are post-translational, not due to intrinsic changes in transcript expression or protein levels.

Dysregulation of nucleosome remodelling deacetylase (NuRD)-complex related genes

Orthogonal studies harnessing the HEK293T overexpression system to determine whether CDKL5 phosphorylates GATAD2A and ZNF219 did not support phosphorylation of these targets by CDKL5 (Supplemental Figs. 12 and 13). Phospho-MS was unable to reliably capture the phosphorylation event on immunoprecipitated ZNF219. Quantitative phospho-MS analysis of GATAD2A Ser100 showed unchanged levels of GATAD2A phosphorylation, whether co-expressed with empty vector, CDKL5 WT or CDKL5 K42R (Supplemental Fig. 13D). Despite this, both GATAD2A and ZNF219 associate with the NuRD complex, a neuronal gene regulatory complex [56, 57]. GATAD2A and CHD4 are part of the core, and ZNF219 is an accessory subunit. A suite of neuronal genes are dysregulated in the Chd4−/− mouse brain [57]. We compared the DE genes in our CDKL5 neuronal RNAseq dataset to the Chd4−/− mouse cortex and identified 11 genes that were downregulated in both datasets (Supplemental Table 11).

Discussion

Phosphoproteomic perturbations in CDKL5 p.(Arg59*) neurons

Our unbiased phosphoproteomics study identified changes in global kinase signalling in CDKL5 p.(Arg59) neurons. KSEA analysis infers kinase-substrate (K-S) relationships, however only ~ 5% of phosphosites have a reported upstream kinase and only ~ 20% of known kinases are well-represented in source databases [58]. Although we identified 454 significantly altered phosphosites, KSEA only recognised 48 K-S relationships (~ 10%). Despite this, all significantly disrupted kinases were in the CMGC family, indicating that compensatory signalling pathways may be occurring in the absence of CDKL5 or that CDKL5 has a critical role in multiple signalling cascades. KSEA demonstrated enrichment of CSNK2A2, CDK1, CDK2, PRKDC, MAPK8 and CLK2 signalling in CDKL5 isogenic controls. CSNK2A2 is the alpha catalytic subunit of the protein kinase enzyme, casein kinase 2 (CK2) that phosphorylates hundreds of substrates with a specific phosphorylation motif [58] and is often overrepresented in phosphoproteome datasets. CDK1 and CDK2 have a critical role in maintaining cell cycle and apoptosis, and cytoskeletal dynamics, processes which are critical to neuronal development [59].

There was enrichment of GSK3α, GSK3β and CDK5 signalling in CDKL5 p.(Arg59*) neurons. CDKL5, GSK3α and GSK3β are closely related in the human kinome, and both CDKL5 and GSK3B are from a specific branch of the CMGC kinases that regulate cilium length [60]. Overexpression of CDK5 and GSK3β cause cytoskeletal abnormalities and microtubule hyperphosphorylation, including MAPT (Tau) [61, 62]. We identified hyperphosphorylation of MAPT in CDKL5 p.(Arg59*) neurons, which has also been reported in Cdkl5-KO mice [63]. GSK3β is expressed in the central nervous system and negatively regulates neurological developmental processes [64]. Loss of CDKL5 enhances AKT/ GSK3β signalling [21], conversely inhibition of GSK3β signalling rescues developmental phenotypes in CDD mouse models [65, 66]. GSK3β overactivation is associated with numerous neurological/developmental conditions and is an attractive therapeutic target [67]. Furthermore, GSK3β inhibition was identified in a high-throughput drug screen for CDD [68]. Targeting GSK3β may be a logical therapeutic approach for CDD.

We identified increased phosphorylation of cytoskeletal and microtubule-related proteins (MAPs), notably MAPT (Tau), MAP1A, MAP1B, MAP2, NCAM1 and DCX, in CDKL5 p.(Arg59*) neurons. MAPs are critical to neuronal development, maturation and maintenance and post-translational phosphorylation affects microtubule stability, function and localisation. For example, phosphorylation releases DCX, MAPT, MAP2, MAP4 and MAP6 from microtubules [69], and their increased phosphorylation in CDKL5 p.(Arg59*) neurons may indicate an intrinsic instability of the neuronal microtubule network. Several MAPs are direct targets of CDKL5 including EB2 (MAPRE2) and MAP1S [8, 9] and broadly CDKL5 regulates microtubule dynamics [8, 9, 70–72].

In CDKL5 p.(Arg59*) neurons there was decreased phosphorylation of histone, RNA-binding and splicing proteins, including six SRSF proteins which facilitate pre-mRNA splicing and RNA regulation [73]. CDKL5 is localised to nuclear speckles, enriched in pre-mRNA splicing factors [74], and may indirectly or directly phosphorylate several chromatin remodeling and DNA methylation proteins including MeCP2 [10, 23, 25], HDAC4 [24], DNMT1 [75], SOX9 [76] and SMAD3 [77].

We searched for new targets with the CDKL5 consensus motif RPX(Sp/Tp)[A/G/P] [8, 78] and identified four new potential CDKL5 targets; PPP1R35, GTF2I, ZNF219 and GATAD2A. These targets have cellular functions consistent with the known functions of CDKL5. PPP1R35 is a putative regulator of Protein Phosphatase 1 (PP1) and is a centrosomal-associated protein that regulates centriole number and cilial length. GTF2I interacts with the basal transcriptional machinery and links specific cellular responsive activator complexes, particularly in brain tissues. GATAD2A and ZNF219 belong to the NuRD complex, which regulates neuronal activity-dependent genes [56], and synaptic connectivity [57]. Kinase-substrate evidence was strongest for CDKL5 being the kinase phosphorylating PPP1R35 and GTF2I, whilst GATAD2A and ZNF219 ranked lower.

PPP1R35 (PP1 regulatory subunit 35) a cilial and centrosomal protein as a new target of CDKL5

Our phosphoproteomics data from human iPSC-derived neurons and subsequent validation by IP and MS supports PPP1R35 as a new CDKL5 target. PPP1R35 is required for centriole to centrosome conversion [79], cell cycle progression [80], for centriole duplication, and in ciliogenesis [80, 81]. Regulation of cell cycle and cilial function is critical for neurogenesis and neuronal maturation [82]. Human congenital ciliopathies are caused by defects in centriolar proteins and are the underlying cause of some cases of microcephaly [83, 84]. PPP1R35 is a candidate ciliopathy gene, associated with microcephaly, intellectual disability and global developmental delay [80, 85, 86]. Ppp1r35-/- mice had developmentally delayed embryogenesis and severe morphological defects, with a lack of primary cilia [81].

PPP1R35 directly interacts with CEP131 [87], a direct CDKL5 phosphorylation target [9]. CEP131 is a centrosomal protein responsible for formation of primary cilia [88]. Rotatin (RTTN) is another PPP1R35 interacting protein and is associated with microcephaly and centriole length regulation [87]. RTTN regulates the structure of primary cilia and centrioles, and in mature neurons may affect neuronal migration [89]. PPP1R35 is critical for centriole elongation and recruiting microtubule-binding elongation machinery, processes that are impaired in CDKL5 [8, 9]. CDKL5 is present at the centrosome, is involved in ciliogenesis [60, 71, 90] and in regulating proper cilial length [91]. This suggests that CDKL5 may regulate cilia through direct phosphorylation of both CEP131 and PPP1R35.

Intracellular CDKL5 localisation is partly driven by Dyrk1a-mediated phosphorylation [92] and, upon NMDA-receptor driven stimulation, can be dephosphorylated by PP1, which confines CDKL5 to the cytoplasm [93]. Interestingly, PPP1R35 is a regulatory subunit of PP1 [94] and most PP1-regulatory proteins inhibit PP1 phosphatase activity. Phosphorylation of PP1-regulatory proteins (e.g. PPP1R35) provides an additional level of PP1 regulation. It could be reasonably speculated that in response to external stimuli such as NMDA-receptor stimulation PPP1R35 is part of a feedback loop regulating PP1 phosphorylation, which in turn regulates CDKL5.

The Ser52 residue of PPP1R35 is one of three highly conserved, and closely located serine residues often identified in large-scale phosphoproteomic studies, highlighting their biological significance [95–97]. Mutagenesis of any of these three serines did not impair PPP1R35 interacting with RTTN or centriole formation [87]. However adjacent to the conserved serine residues at amino acids 77–81 is a putative PP1 binding and regulation site [94, 98] whilst amino acids 103–253 regulate centrosome biogenesis [79]. Consequently, it remains to be determined whether CDKL5-mediated phosphorylation of PPP1R35 at Ser52 is critical for PP1 regulation, centrosomal biogenesis or cilia length.

GTF2I (General transcription factor II–I), a gene regulatory protein, as a new target of CDKL5

The second novel CDKL5 target we identified was GTF2I, with phosphorylation occurring at Ser674. According to Uniprot, Ser674 in the canonical protein (Uniprot P78347) corresponds to S633 in isoform 2 (P78347-2). Site-directed mutagenesis of Ser633 in isoform 2 (Ser674 in the canonical protein) impairs GTF2I activity on the c-fos promoter, but does not affect DNA-binding of GTF2I [99]. GTF2I is highly expressed in the brain, predominantly in neurons [100] and controls axon guidance, calcium signalling, neuronal apoptosis [101], neuronal differentiation [102] and cell cycle by regulating a suite of specific neuronal development genes [53, 103, 104]. The activity and specificity of GTF2I is regulated by phosphorylation at serine or tyrosine residues, and a number of kinases have been implicated in GTF2I regulation including Btk, c-Src, JAK2, ERK/MAPK and cGMP. Specifically, ERK is reported to phosphorylate GTF2I at the same site (Ser674) as we report for CDKL5 [99]. GTF2I is a multifactorial kinase target involved in many signalling pathways, and it is possible that there is more than one kinase that phosphorylates at this site. Phosphorylation may provide a rapid and reversible transactivation of GTF2I and expression of GTF2I-regulated genes.

GTF2I binds to core promoter elements and upstream elements to regulate transcription by coordinating the formation of a multiprotein complex at the cFOS promoter, linking specific signal responsive activator complexes [105]. The cFOS promoter is a highly responsive immediate-early gene promoter that responds transiently from a range of extracellular stimuli and is essential in determining neuronal survival [106]. When hippocampal cFOS expression is eliminated, neuronal apoptosis is increased and mice experience heightened excitability and severe kainic-acid induced seizures [107]. Interestingly, several studies report severely reduced cFOS expression in V1 cortex of Cdkl5−/y mutants [108] with impairment in the whisker tactile stimulation-induced neuronal activation [109], and reduced cFOS expression persisted with age [110]. If CDKL5 regulates phosphorylation of GTF2I, resulting in altered cFOS activity, dysregulation of this pathway may explain the seizure-like phenotype and increased neuronal apoptosis in the absence of CDKL5 [77, 111].

GTF2I also directly interacts with PolII and Elongin A (ELOA) in response to stress, and regulates transcription of the DNMT1 and EFR3A genes [112]. DNMT1 is phosphorylated by CDKL5 [75], although not within the CDKL5 consensus motif [27]; however ELOA is directly phosphorylated by CDKL5 in the known CDKL5 phosphorylation motif in response to DNA damage [78].

GTF2I and the functionally related GTF2IRD1 are two of up to 28 genes deleted in the microdeletion syndrome Williams-Beuren Syndrome (WS; OMIM #194,050). WS is characterised by craniofacial dysmorphology, intellectual disability and hyper-sociability and specifically GTF2I deletion explains many of the social and cognitive features of WS [113]. Mouse models of WS (either single or combined GTF2I/GTF2IRD1 gene knockouts) showed transcriptional activity changes restricted to chromatin modifier and synaptic protein genes [114], and the function of GTF2I was enriched for regulating signal transduction proteins, specifically phosphorylation and WNT signalling [114]. Despite a 50% knockdown of GTF2I in the mouse model, transcriptional changes were still quite subtle [114]. In autism spectrum disorders, individuals with GTF2I have hyposociability [115], the opposite to WS patients who are hypersocial. Mice with a single copy of Gtf2i had increased axonal outgrowth, whilst mice with 3 copies of Gtf2i had decreased axonal outgrowth [116]. This suggests a gene-dose effect of GTF2I could disrupt neuronal transcriptional circuits during early developmental stages [103]. This is in line with other animal models of chromatin modifier genes (e.g. MeCP2) with relatively modest transcriptional dysregulation [117–119], implying that these genes require precise transcriptional dosing for correct neuronal development. It is likely that chromatin modifying proteins including GTF2I and MECP2 regulate the dynamics of neuronal gene expression, and fine-tuning their activity via CDKL5-mediated phosphorylation regulates activity and specificity.

Upon decreased GTF2I phosphorylation in CDKL5-deficent neurons, we may anticipate impaired transcriptional and regulatory activity of GTF2I, as demonstrated upon site-directed mutagenesis of Ser674 in GTF2I [99]. A study of both WS brain biopsies and Gtf2I knockout mouse cortex revealed a suite of downregulated genes likely regulated by GTF2I [54]. Interestingly, we demonstrated 19 genes dysregulated in CDKL5 p.(Arg59*) neurons were also dysregulated in GTF2I models. Specifically, BEN domain containing 4 (BEND4) is a gene directly repressed by GTF2I [53], and BEND4 and GTF2I levels are negatively correlated in the human brain [53]. We showed a significant increase in BEND4 expression in CDKL5 p.Arg59* neurons, without changes to GTF2I transcript or protein levels. It is possible that if CDKL5 does not actively phosphorylate GTF2I the transcriptional repressor activity of GTF2I is impaired, and dysregulation of a suite of genes, including BEND4 expression occurs. Little is known on the function of BEND4, but it is part of a family of neural repressor transcription factors [120]. Patients with missense variants in BEND4 had acute neurological deterioration following infections, lost most social and language skills, which was associated with a pontine cyst, calcification, and cerebellar atrophy [121]. Our findings suggest that CDKL5 may regulate BEND4 and a suite of other neuronal genes via GTF2I phosphorylation.

Are ZNF219 and GATAD2A CDKL5 phosphotargets?

Our phosphoproteomics data from CDKL5 neurons identified GATAD2A and ZNF219 as potential CDKL5 targets. Although our orthogonal overexpression studies in HEK293 failed to reveal significant differences in phosphorylation by CDKL5, overexpression of components of the NuRD complex may disrupt endogenous cell signalling pathways, or potentially prevent correct NuRD subunit composition by interfering with the native NuRD stoichiometry [122], which can vary in composition in a cellular context [123] and tissue specific manner [124]. Interactions with core subunits including GATAD2A [125, 126] and non-canonical proteins such as ZNF219 [127] as well as post-translational modifications [124] regulate NuRD complex activity.

The ZNF219 Ser114 phosphorylation site facilitates interaction between ZNF219 and the NuRD complex [127] which may impact cell-specific regulation of downstream target genes. While the mouse homologue of GATAD2A, also known as p66α, was phosphorylated at Ser96 (corresponds to human Ser100) in response to neuronal activation, histone modifications and neuronal rewiring [128].

The NuRD complex is a critical epigenetic regulator during neuronal development [57, 129], and maintains experience-dependent neuronal plasticity [123]. CDKL5-mediated phosphorylation of NuRD proteins including ZNF219 and GATAD2A may ensure accurate transcriptional activity of the NuRD complex in the brain. Although our orthogonal studies were not able to determine whether CDKL5 directly phosphorylates GATAD2A or ZNF219, we assessed whether there were transcriptional responses which may support dysregulation of the NuRD complex. Interestingly, our RNAseq data in CDKL5 p.(Arg59*) neurons identified 11 genes that were also downregulated in Chd4−/− mice [122]. Knockout of Chd4, a key subunit of the NuRD complex, dysregulates a suite of genes in the mouse cortex [57]. CDKL5 may be a key kinase that modulates phosphorylation of ZNF219 and/or GATAD2A and subsequent NuRD activity, and further investigation is clearly warranted. Researchers have obtained more reliable results utilising an in vitro rabbit reticulocyte lysate expression system when studying the NuRD complex to better recapitulate native complex stoichiometry, which could be a future approach to validate these potential CDKL5 targets [130].

Conclusion

For the first time our data demonstrates that pathogenic variants in CDKL5 may inhibit phosphorylation of PPP1R35, GTF2I, GATAD2A and ZNF219. We performed phosphoproteomics in tissue models of iPSC-derived neurons from CDD patients, compared to isogenic controls and validated protein phosphorylation in transfected HEK293T cells. These human-derived models are more relevant to understanding CDD disease relevant molecular pathways than animal models. However, tissue models are themselves distinct entities with different cellular structure, epigenetics and microenvironments, which may alter molecular pathways in comparison to the patients from which the iPSCs were derived. Further validation of the identified protein markers should be performed in more complex iPSC-derived brain organoids and in primary tissue from patients wherever possible. Uncovering the molecular pathways regulated by CDKL5 may enable development of new targeted treatments for CDD and associated disorders.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 7770 KB)

Supplementary file2 (TXT 1459 KB)

Supplementary file3 (TXT 18697 KB)

Supplementary file4 (TXT 248 KB)

Supplementary file5 (TXT 153 KB)

Abbreviations

CDKL5 Cyclin-dependent kinase-like 5

CDD CDKL5 deficiency disorder

NuRD Nucleosome remodelling deacetylase complex

RTT Rett syndrome

iPSC Induced pluripotent stem cells

WS Williams-Beuren syndrome

KSEA Kinase-substrate enrichment analysis

Acknowledgements

The research conducted at the Murdoch Children’s Research Institute (MCRI) was supported by the State Government of Victoria's Operational Infrastructure Support Program. Funding to NVB was provided by the Foundation for Children Project Grant (2018-16), Murdoch Children’s Research Institute Strategic Pilot Project in Stem Cell and Genomic Medicine Research Grant, Million Dollar Bike Ride pilot grant from the Orphan Disease Center of the University of Pennsylvania (MDBR-20-106-CDKL5), the CDKL5 Forum Junior Fellowship from the Loulou Foundation, the Medical Research Future Funds (MRFF) Stem Cell Therapies Mission (MRF2007465), MCRI Near Miss grant, MCRI Strategic Pilot Project in Stem Cell and Genomics Medicine and the VESKI Near Miss Pilot Award. The Chair in Genomic Medicine awarded to JC is generously supported by The Royal Children’s Hospital Foundation. We acknowledge the Bio21 MS and Proteomics Facility for the provision of instrumentation, training and technical support. We thank Alison Graham and Sara Howden from the Gene Editing Core facility at MCRI for generating the CDKL5 iPSC lines, Molly Ellery for assisting with cloning of CDKL5 targets and Alicia Oshlack for overseeing RNAseq analysis. The authors acknowledge the facilities, and the scientific and technical assistance of Murdoch Children’s Research Institute iPSC and Gene Editing (GE) Core Facility. MCRI iPSC and GE Core Facility was established using a generous donation from the Stafford Fox Medical Research Foundation. It is currently supported by Phenomics Australia (PA), and the Novo Nordisk Foundation reNEW Center for Stem Cell Medicine (NNF21CC0073729). PA is supported by the Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS) program.

Author contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Nicole Van Bergen, Sean Massey, Ching-Seng Ang and Nadia Davidson. The first draft of the manuscript was written by Nicole Van Bergen and Sean Massey. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding

Open Access funding enabled and organized by CAUL and its Member Institutions. This study was funded by State Government of Victoria, Operational Infrastructure Support Program, Nicole J Van Bergen, Foundation for Children, 2018-16, Nicole J Van Bergen, Murdoch Children's Research Institute, Strategic Pilot Project in Stem Cell, Nicole J Van Bergen, Genomic Medicine Research Grant, Nicole J Van Bergen, Near Miss grant, Nicole J Van Bergen, Strategic Pilot Project in Stem Cell, Nicole J Van Bergen, Genomics Medicine, Nicole J Van Bergen, Orphan Disease Center of the University of Pennsylvania, MDBR-20-106-CDKL5, Nicole J Van Bergen, Loulou Foundation, CDKL5 Forum Junior Fellowship, Sean Massey, Medical Research Future Funds (MRFF) Stem Cell Therapies Mission, MRF2007465, Nicole J Van Bergen, Veski, Near Miss Pilot Award, Nicole J Van Bergen, Royal Children's Hospital Foundation, The Chair in Genomic Medicine, John Christodoulou, Stafford Fox Medical Research Foundation, Phenomics Australia, Novo Nordisk Foundation reNEW Center for Stem Cell Medicine, NNF21CC0073729, Nicole J Van Bergen, National Collaborative Research Infrastructure Strategy

Data availability

The de-identified raw data is available upon request.

Declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Ethics approval

All procedures were approved by the local human research ethics committee in accordance with the Helsinki Declaration of 1975, as revised in 2000.

Consent to participate

Written informed consent was obtained from the caregivers.

The original online version of this article was revised to update the Given name and family name as Van Bergen NJ.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

John Christodoulou and Nicole Van Bergen were co-last authors.

Change history

9/10/2024

A Correction to this paper has been published: 10.1007/s00018-024-05421-x
==== Refs
References

1. Kawahata I Fukunaga K Protein kinases and neurodegenerative diseases Int J Mol Sci 2023 10.3390/ijms24065574 38069360
Kawahata I, Fukunaga K (2023) Protein kinases and neurodegenerative diseases. Int J Mol Sci. 10.3390/ijms2406557438069360 10.3390/ijms24065574
2. Olson HE Demarest ST Pestana-Knight EM Swanson LC Iqbal S Lal D Cyclin-dependent kinase-like 5 deficiency disorder: clinical review Pediatr Neurol 2019 97 18 25 10.1016/j.pediatrneurol.2019.02.015 30928302
Olson HE, Demarest ST, Pestana-Knight EM, Swanson LC, Iqbal S, Lal D et al (2019) Cyclin-dependent kinase-like 5 deficiency disorder: clinical review. Pediatr Neurol 97:18–25. 10.1016/j.pediatrneurol.2019.02.01530928302 10.1016/j.pediatrneurol.2019.02.015
3. Weaving LS Christodoulou J Williamson SL Friend KL McKenzie OL Archer H Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation Am J Hum Genet 2004 75 6 1079 1093 10.1086/426462 15492925
Weaving LS, Christodoulou J, Williamson SL, Friend KL, McKenzie OL, Archer H et al (2004) Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am J Hum Genet 75(6):1079–1093. 10.1086/42646215492925 10.1086/426462
4. Tao J Van Esch H Hagedorn-Greiwe M Hoffmann K Moser B Raynaud M Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation Am J Hum Genet 2004 75 6 1149 1154 10.1086/426460 15499549
Tao J, Van Esch H, Hagedorn-Greiwe M, Hoffmann K, Moser B, Raynaud M et al (2004) Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. Am J Hum Genet 75(6):1149–1154. 10.1086/42646015499549 10.1086/426460
5. Arora S Goodall S Viney R Einfeld S Societal cost of childhood intellectual disability in Australia J Intellect Disabil Res 2020 64 7 524 537 10.1111/jir.12732 32329168
Arora S, Goodall S, Viney R, Einfeld S (2020) Societal cost of childhood intellectual disability in Australia. J Intellect Disabil Res 64(7):524–537. 10.1111/jir.1273232329168 10.1111/jir.12732
6. Fehr S Wilson M Downs J Williams S Murgia A Sartori S The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy Eur J Hum Genet 2013 21 3 266 273 10.1038/ejhg.2012.156 22872100
Fehr S, Wilson M, Downs J, Williams S, Murgia A, Sartori S et al (2013) The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. Eur J Hum Genet 21(3):266–273. 10.1038/ejhg.2012.15622872100 10.1038/ejhg.2012.156
7. Smeets EE Pelc K Dan B Rett syndrome Mol Syndromol 2012 2 3–5 113 127 22670134
Smeets EE, Pelc K, Dan B (2012) Rett syndrome. Mol Syndromol 2(3–5):113–12722670134
8. Baltussen LL Negraes PD Silvestre M Claxton S Moeskops M Christodoulou E Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics EMBO J 2018 10.15252/embj.201899763 30266824
Baltussen LL, Negraes PD, Silvestre M, Claxton S, Moeskops M, Christodoulou E et al (2018) Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics. EMBO J. 10.15252/embj.20189976330266824 10.15252/embj.201899763
9. Munoz IM Morgan ME Peltier J Weiland F Gregorczyk M Brown FC Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase EMBO J 2018 10.15252/embj.201899559 30266825
Munoz IM, Morgan ME, Peltier J, Weiland F, Gregorczyk M, Brown FC et al (2018) Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase. EMBO J. 10.15252/embj.20189955930266825 10.15252/embj.201899559
10. Williamson SL Giudici L Kilstrup-Nielsen C Gold W Pelka GJ Tam PP A novel transcript of cyclin-dependent kinase-like 5 (CDKL5) has an alternative C-terminus and is the predominant transcript in brain Hum Genet 2012 131 2 187 200 10.1007/s00439-011-1058-x 21748340
Williamson SL, Giudici L, Kilstrup-Nielsen C, Gold W, Pelka GJ, Tam PP et al (2012) A novel transcript of cyclin-dependent kinase-like 5 (CDKL5) has an alternative C-terminus and is the predominant transcript in brain. Hum Genet 131(2):187–200. 10.1007/s00439-011-1058-x21748340 10.1007/s00439-011-1058-x
11. Fichou Y Nectoux J Bahi-Buisson N Chelly J Bienvenu T An isoform of the severe encephalopathy-related CDKL5 gene, including a novel exon with extremely high sequence conservation, is specifically expressed in brain J Hum Genet 2011 56 1 52 57 10.1038/jhg.2010.143 21124335
Fichou Y, Nectoux J, Bahi-Buisson N, Chelly J, Bienvenu T (2011) An isoform of the severe encephalopathy-related CDKL5 gene, including a novel exon with extremely high sequence conservation, is specifically expressed in brain. J Hum Genet 56(1):52–57. 10.1038/jhg.2010.14321124335 10.1038/jhg.2010.143
12. Wang IT Allen M Goffin D Zhu X Fairless AH Brodkin ES Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice Proc Natl Acad Sci U S A 2012 109 52 21516 21521 10.1073/pnas.1216988110 23236174
Wang IT, Allen M, Goffin D, Zhu X, Fairless AH, Brodkin ES et al (2012) Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. Proc Natl Acad Sci U S A 109(52):21516–21521. 10.1073/pnas.121698811023236174 10.1073/pnas.1216988110
13. Kilstrup-Nielsen C Rusconi L La Montanara P Ciceri D Bergo A Bedogni F What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy Neural Plast 2012 2012 728267 10.1155/2012/728267 22779007
Kilstrup-Nielsen C, Rusconi L, La Montanara P, Ciceri D, Bergo A, Bedogni F et al (2012) What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy. Neural Plast 2012:728267. 10.1155/2012/72826722779007 10.1155/2012/728267
14. Rusconi L Salvatoni L Giudici L Bertani I Kilstrup-Nielsen C Broccoli V CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail J Biol Chem 2008 283 44 30101 30111 10.1074/jbc.M804613200 18701457
Rusconi L, Salvatoni L, Giudici L, Bertani I, Kilstrup-Nielsen C, Broccoli V et al (2008) CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail. J Biol Chem 283(44):30101–30111. 10.1074/jbc.M80461320018701457 10.1074/jbc.M804613200
15. Rusconi L Kilstrup-Nielsen C Landsberger N Extrasynaptic N-methyl-d-aspartate (NMDA) receptor stimulation induces cytoplasmic translocation of the CDKL5 kinase and its proteasomal degradation J Biol Chem 2011 286 42 36550 36558 10.1074/jbc.M111.235630 21832092
Rusconi L, Kilstrup-Nielsen C, Landsberger N (2011) Extrasynaptic N-methyl-d-aspartate (NMDA) receptor stimulation induces cytoplasmic translocation of the CDKL5 kinase and its proteasomal degradation. J Biol Chem 286(42):36550–36558. 10.1074/jbc.M111.23563021832092 10.1074/jbc.M111.235630
16. Ricciardi S Ungaro F Hambrock M Rademacher N Stefanelli G Brambilla D CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons Nat Cell Biol 2012 14 9 911 923 10.1038/ncb2566 22922712
Ricciardi S, Ungaro F, Hambrock M, Rademacher N, Stefanelli G, Brambilla D et al (2012) CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons. Nat Cell Biol 14(9):911–923. 10.1038/ncb256622922712 10.1038/ncb2566
17. Valli E Trazzi S Fuchs C Erriquez D Bartesaghi R Perini G CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells Biochim Biophys Acta 2012 1819 11–12 1173 1185 10.1016/j.bbagrm.2012.08.001 22921766
Valli E, Trazzi S, Fuchs C, Erriquez D, Bartesaghi R, Perini G et al (2012) CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells. Biochim Biophys Acta 1819(11–12):1173–1185. 10.1016/j.bbagrm.2012.08.00122921766 10.1016/j.bbagrm.2012.08.001
18. Chen Q Zhu YC Yu J Miao S Zheng J Xu L CDKL5, a protein associated with rett syndrome, regulates neuronal morphogenesis via Rac1 signaling J Neurosci 2010 30 38 12777 12786 10.1523/JNEUROSCI.1102-10.2010 20861382
Chen Q, Zhu YC, Yu J, Miao S, Zheng J, Xu L et al (2010) CDKL5, a protein associated with rett syndrome, regulates neuronal morphogenesis via Rac1 signaling. J Neurosci 30(38):12777–12786. 10.1523/JNEUROSCI.1102-10.201020861382 10.1523/JNEUROSCI.1102-10.2010
19. Zhu YC Li D Wang L Lu B Zheng J Zhao SL Palmitoylation-dependent CDKL5-PSD-95 interaction regulates synaptic targeting of CDKL5 and dendritic spine development Proc Natl Acad Sci U S A 2013 110 22 9118 9123 10.1073/pnas.1300003110 23671101
Zhu YC, Li D, Wang L, Lu B, Zheng J, Zhao SL et al (2013) Palmitoylation-dependent CDKL5-PSD-95 interaction regulates synaptic targeting of CDKL5 and dendritic spine development. Proc Natl Acad Sci U S A 110(22):9118–9123. 10.1073/pnas.130000311023671101 10.1073/pnas.1300003110
20. Amendola E Zhan Y Mattucci C Castroflorio E Calcagno E Fuchs C Mapping pathological phenotypes in a mouse model of CDKL5 disorder PLoS ONE 2014 9 5 e91613 10.1371/journal.pone.0091613 24838000
Amendola E, Zhan Y, Mattucci C, Castroflorio E, Calcagno E, Fuchs C et al (2014) Mapping pathological phenotypes in a mouse model of CDKL5 disorder. PLoS ONE 9(5):e91613. 10.1371/journal.pone.009161324838000 10.1371/journal.pone.0091613
21. Fuchs C Trazzi S Torricella R Viggiano R De Franceschi M Amendola E Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3beta signaling Neurobiol Dis 2014 70 53 68 10.1016/j.nbd.2014.06.006 24952363
Fuchs C, Trazzi S, Torricella R, Viggiano R, De Franceschi M, Amendola E et al (2014) Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3beta signaling. Neurobiol Dis 70:53–68. 10.1016/j.nbd.2014.06.00624952363 10.1016/j.nbd.2014.06.006
22. Lin C Franco B Rosner MR CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders Hum Mol Genet 2005 14 24 3775 3786 10.1093/hmg/ddi391 16330482
Lin C, Franco B, Rosner MR (2005) CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders. Hum Mol Genet 14(24):3775–3786. 10.1093/hmg/ddi39116330482 10.1093/hmg/ddi391
23. Bertani I Rusconi L Bolognese F Forlani G Conca B De Monte L Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation J Biol Chem 2006 281 42 32048 32056 10.1074/jbc.M606325200 16935860
Bertani I, Rusconi L, Bolognese F, Forlani G, Conca B, De Monte L et al (2006) Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation. J Biol Chem 281(42):32048–32056. 10.1074/jbc.M60632520016935860 10.1074/jbc.M606325200
24. Trazzi S Fuchs C Viggiano R De Franceschi M Valli E Jedynak P HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder Hum Mol Genet 2016 25 18 3887 3907 10.1093/hmg/ddw231 27466189
Trazzi S, Fuchs C, Viggiano R, De Franceschi M, Valli E, Jedynak P et al (2016) HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder. Hum Mol Genet 25(18):3887–3907. 10.1093/hmg/ddw23127466189 10.1093/hmg/ddw231
25. Mari F Azimonti S Bertani I Bolognese F Colombo E Caselli R CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome Hum Mol Genet 2005 14 14 1935 1946 10.1093/hmg/ddi198 15917271
Mari F, Azimonti S, Bertani I, Bolognese F, Colombo E, Caselli R et al (2005) CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum Mol Genet 14(14):1935–1946. 10.1093/hmg/ddi19815917271 10.1093/hmg/ddi198
26. Sekiguchi M Katayama S Hatano N Shigeri Y Sueyoshi N Kameshita I Identification of amphiphysin 1 as an endogenous substrate for CDKL5, a protein kinase associated with X-linked neurodevelopmental disorder Arch Biochem Biophys 2013 535 2 257 267 10.1016/j.abb.2013.04.012 23651931
Sekiguchi M, Katayama S, Hatano N, Shigeri Y, Sueyoshi N, Kameshita I (2013) Identification of amphiphysin 1 as an endogenous substrate for CDKL5, a protein kinase associated with X-linked neurodevelopmental disorder. Arch Biochem Biophys 535(2):257–267. 10.1016/j.abb.2013.04.01223651931 10.1016/j.abb.2013.04.012
27. Van Bergen NJ Massey S Quigley A Rollo B Harris AR Kapsa RMI CDKL5 deficiency disorder: molecular insights and mechanisms of pathogenicity to fast-track therapeutic development Biochem Soc Trans 2022 50 4 1207 1224 10.1042/BST20220791 35997111
Van Bergen NJ, Massey S, Quigley A, Rollo B, Harris AR, Kapsa RMI et al (2022) CDKL5 deficiency disorder: molecular insights and mechanisms of pathogenicity to fast-track therapeutic development. Biochem Soc Trans 50(4):1207–1224. 10.1042/BST2022079135997111 10.1042/BST20220791
28. Van Bergen NJ Massey S Stait T Ellery M Reljic B Formosa LE Abnormalities of mitochondrial dynamics and bioenergetics in neuronal cells from CDKL5 deficiency disorder Neurobiol Dis 2021 155 105370 10.1016/j.nbd.2021.105370 33905871
Van Bergen NJ, Massey S, Stait T, Ellery M, Reljic B, Formosa LE et al (2021) Abnormalities of mitochondrial dynamics and bioenergetics in neuronal cells from CDKL5 deficiency disorder. Neurobiol Dis 155:105370. 10.1016/j.nbd.2021.10537033905871 10.1016/j.nbd.2021.105370
29. Nasr B Chatterton R Yong JHM Jamshidi P D'Abaco GM Bjorksten AR Self-organized nanostructure modified microelectrode for sensitive electrochemical glutamate detection in stem cells-derived brain organoids Biosensors (Basel) 2018 10.3390/bios8010014 29401739
Nasr B, Chatterton R, Yong JHM, Jamshidi P, D’Abaco GM, Bjorksten AR et al (2018) Self-organized nanostructure modified microelectrode for sensitive electrochemical glutamate detection in stem cells-derived brain organoids. Biosensors (Basel). 10.3390/bios801001429401739 10.3390/bios8010014
30. Denham M Dottori M Neural differentiation of induced pluripotent stem cells Methods Mol Biol 2011 793 99 110 10.1007/978-1-61779-328-8_7 21913096
Denham M, Dottori M (2011) Neural differentiation of induced pluripotent stem cells. Methods Mol Biol 793:99–110. 10.1007/978-1-61779-328-8_721913096 10.1007/978-1-61779-328-8_7
31. Alshawaf AJ Antonic A Skafidas E Ng DC Dottori M WDR62 regulates early neural and glial progenitor specification of human pluripotent stem cells Stem Cells Int 2017 2017 7848932 10.1155/2017/7848932 28690640
Alshawaf AJ, Antonic A, Skafidas E, Ng DC, Dottori M (2017) WDR62 regulates early neural and glial progenitor specification of human pluripotent stem cells. Stem Cells Int 2017:7848932. 10.1155/2017/784893228690640 10.1155/2017/7848932
32. D'Abaco GM Mattei C Nasr B Hudson EJ Alshawaf AJ Chana G Graphene foam as a biocompatible scaffold for culturing human neurons R Soc Open Sci 2018 5 3 171364 10.1098/rsos.171364 29657752
D’Abaco GM, Mattei C, Nasr B, Hudson EJ, Alshawaf AJ, Chana G et al (2018) Graphene foam as a biocompatible scaffold for culturing human neurons. R Soc Open Sci 5(3):171364. 10.1098/rsos.17136429657752 10.1098/rsos.171364
33. Dobin A Davis CA Schlesinger F Drenkow J Zaleski C Jha S STAR: ultrafast universal RNA-seq aligner Bioinformatics 2013 29 1 15 21 10.1093/bioinformatics/bts635 23104886
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S et al (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29(1):15–21. 10.1093/bioinformatics/bts63523104886 10.1093/bioinformatics/bts635
34. Picard: Picard Tools. http://broadinstitute.github.io/picard (2023)
35. Frankish A Diekhans M Jungreis I Lagarde J Loveland JE Mudge JM Gencode 2021 Nucleic Acids Res 2021 49 D1 D916 D923 10.1093/nar/gkaa1087 33270111
Frankish A, Diekhans M, Jungreis I, Lagarde J, Loveland JE, Mudge JM et al (2021) Gencode 2021. Nucleic Acids Res 49(D1):D916–D923. 10.1093/nar/gkaa108733270111 10.1093/nar/gkaa1087
36. Liao Y Smyth GK Shi W featureCounts: an efficient general purpose program for assigning sequence reads to genomic features Bioinformatics 2014 30 7 923 930 10.1093/bioinformatics/btt656 24227677
Liao Y, Smyth GK, Shi W (2014) featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30(7):923–930. 10.1093/bioinformatics/btt65624227677 10.1093/bioinformatics/btt656
37. Robinson JT Thorvaldsdottir H Winckler W Guttman M Lander ES Getz G Integrative genomics viewer Nat Biotechnol 2011 29 1 24 26 10.1038/nbt.1754 21221095
Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G et al (2011) Integrative genomics viewer. Nat Biotechnol 29(1):24–26. 10.1038/nbt.175421221095 10.1038/nbt.1754
38. Robinson MD McCarthy DJ Smyth GK edgeR: a Bioconductor package for differential expression analysis of digital gene expression data Bioinformatics 2010 26 1 139 140 10.1093/bioinformatics/btp616 19910308
Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26(1):139–140. 10.1093/bioinformatics/btp61619910308 10.1093/bioinformatics/btp616
39. Cox J Neuhauser N Michalski A Scheltema RA Olsen JV Mann M Andromeda: a peptide search engine integrated into the MaxQuant environment J Proteome Res 2011 10 4 1794 1805 10.1021/pr101065j 21254760
Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M (2011) Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res 10(4):1794–1805. 10.1021/pr101065j21254760 10.1021/pr101065j
40. Ashburner M Ball CA Blake JA Botstein D Butler H Cherry JM Gene ontology: tool for the unification of biology Gene Ontol Consort Nat Genet 2000 25 1 25 29 10.1038/75556
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM et al (2000) Gene ontology: tool for the unification of biology. Gene Ontol Consort Nat Genet 25(1):25–29. 10.1038/7555610.1038/75556
41. The Gene Ontology C. The gene ontology resource: 20 years and still GOing strong. Nucleic Acids Res. 2019;47(D1):D330–D8. 10.1093/nar/gky1055
42. Szklarczyk D Gable AL Lyon D Junge A Wyder S Huerta-Cepas J STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets Nucleic Acids Res 2019 47 D1 D607 D613 10.1093/nar/gky1131 30476243
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J et al (2019) STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 47(D1):D607–D613. 10.1093/nar/gky113130476243 10.1093/nar/gky1131
43. Szklarczyk D Gable AL Nastou KC Lyon D Kirsch R Pyysalo S The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets Nucleic Acids Res 2021 49 D1 D605 D612 10.1093/nar/gkaa1074 33237311
Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S et al (2021) The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res 49(D1):D605–D612. 10.1093/nar/gkaa107433237311 10.1093/nar/gkaa1074
44. Bailey TL Johnson J Grant CE Noble WS The MEME suite Nucleic Acids Res 2015 43 W1 W39 49 10.1093/nar/gkv416 25953851
Bailey TL, Johnson J, Grant CE, Noble WS (2015) The MEME suite. Nucleic Acids Res 43(W1):W39-49. 10.1093/nar/gkv41625953851 10.1093/nar/gkv416
45. Cheng A Grant CE Noble WS Bailey TL MoMo: discovery of statistically significant post-translational modification motifs Bioinformatics 2019 35 16 2774 2782 10.1093/bioinformatics/bty1058 30596994
Cheng A, Grant CE, Noble WS, Bailey TL (2019) MoMo: discovery of statistically significant post-translational modification motifs. Bioinformatics 35(16):2774–2782. 10.1093/bioinformatics/bty105830596994 10.1093/bioinformatics/bty1058
46. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 2015;43(Database issue):D512–20. 10.1093/nar/gku1267
47. Johnson JL Yaron TM Huntsman EM Kerelsky A Song J Regev A An atlas of substrate specificities for the human serine/threonine kinome Nature 2023 613 7945 759 766 10.1038/s41586-022-05575-3 36631611
Johnson JL, Yaron TM, Huntsman EM, Kerelsky A, Song J, Regev A et al (2023) An atlas of substrate specificities for the human serine/threonine kinome. Nature 613(7945):759–766. 10.1038/s41586-022-05575-336631611 10.1038/s41586-022-05575-3
48. Yaffe MB Leparc GG Lai J Obata T Volinia S Cantley LC A motif-based profile scanning approach for genome-wide prediction of signaling pathways Nat Biotechnol 2001 19 4 348 353 10.1038/86737 11283593
Yaffe MB, Leparc GG, Lai J, Obata T, Volinia S, Cantley LC (2001) A motif-based profile scanning approach for genome-wide prediction of signaling pathways. Nat Biotechnol 19(4):348–353. 10.1038/8673711283593 10.1038/86737
49. MacLean B Tomazela DM Shulman N Chambers M Finney GL Frewen B Skyline: an open source document editor for creating and analyzing targeted proteomics experiments Bioinformatics 2010 26 7 966 968 10.1093/bioinformatics/btq054 20147306
MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B et al (2010) Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26(7):966–968. 10.1093/bioinformatics/btq05420147306 10.1093/bioinformatics/btq054
50. Desiere F, Deutsch EW, King NL, Nesvizhskii AI, Mallick P, Eng J, et al. The peptide atlas project. Nucleic Acids Res. 2006;34(Database issue):D655–8. 10.1093/nar/gkj040
51. Advani G Lim YC Catimel B Lio DSS Ng NLY Chueh AC Csk-homologous kinase (Chk) is an efficient inhibitor of Src-family kinases but a poor catalyst of phosphorylation of their C-terminal regulatory tyrosine Cell Commun Signal 2017 15 1 29 10.1186/s12964-017-0186-x 28784162
Advani G, Lim YC, Catimel B, Lio DSS, Ng NLY, Chueh AC et al (2017) Csk-homologous kinase (Chk) is an efficient inhibitor of Src-family kinases but a poor catalyst of phosphorylation of their C-terminal regulatory tyrosine. Cell Commun Signal 15(1):29. 10.1186/s12964-017-0186-x28784162 10.1186/s12964-017-0186-x
52. Hoque A Williamson NA Ameen SS Ciccotosto GD Hossain MI Oakhill JS Quantitative proteomic analyses of dynamic signalling events in cortical neurons undergoing excitotoxic cell death Cell Death Dis 2019 10 3 213 10.1038/s41419-019-1445-0 30824683
Hoque A, Williamson NA, Ameen SS, Ciccotosto GD, Hossain MI, Oakhill JS et al (2019) Quantitative proteomic analyses of dynamic signalling events in cortical neurons undergoing excitotoxic cell death. Cell Death Dis 10(3):213. 10.1038/s41419-019-1445-030824683 10.1038/s41419-019-1445-0
53. Adamo A Atashpaz S Germain PL Zanella M D'Agostino G Albertin V 7q11.23 dosage-dependent dysregulation in human pluripotent stem cells affects transcriptional programs in disease-relevant lineages Nat Genet 2015 47 2 132 141 10.1038/ng.3169 25501393
Adamo A, Atashpaz S, Germain PL, Zanella M, D’Agostino G, Albertin V et al (2015) 7q11.23 dosage-dependent dysregulation in human pluripotent stem cells affects transcriptional programs in disease-relevant lineages. Nat Genet 47(2):132–141. 10.1038/ng.316925501393 10.1038/ng.3169
54. Barak B Zhang Z Liu Y Nir A Trangle SS Ennis M Neuronal deletion of Gtf2i, associated with Williams syndrome, causes behavioral and myelin alterations rescuable by a remyelinating drug Nat Neurosci 2019 22 5 700 708 10.1038/s41593-019-0380-9 31011227
Barak B, Zhang Z, Liu Y, Nir A, Trangle SS, Ennis M et al (2019) Neuronal deletion of Gtf2i, associated with Williams syndrome, causes behavioral and myelin alterations rescuable by a remyelinating drug. Nat Neurosci 22(5):700–708. 10.1038/s41593-019-0380-931011227 10.1038/s41593-019-0380-9
55. Henrichsen CN Csardi G Zabot MT Fusco C Bergmann S Merla G Using transcription modules to identify expression clusters perturbed in Williams-Beuren syndrome PLoS Comput Biol 2011 7 1 e1001054 10.1371/journal.pcbi.1001054 21304579
Henrichsen CN, Csardi G, Zabot MT, Fusco C, Bergmann S, Merla G et al (2011) Using transcription modules to identify expression clusters perturbed in Williams-Beuren syndrome. PLoS Comput Biol 7(1):e1001054. 10.1371/journal.pcbi.100105421304579 10.1371/journal.pcbi.1001054
56. Yang Y Yamada T Hill KK Hemberg M Reddy NC Cho HY Chromatin remodeling inactivates activity genes and regulates neural coding Science 2016 353 6296 300 305 10.1126/science.aad4225 27418512
Yang Y, Yamada T, Hill KK, Hemberg M, Reddy NC, Cho HY et al (2016) Chromatin remodeling inactivates activity genes and regulates neural coding. Science 353(6296):300–305. 10.1126/science.aad422527418512 10.1126/science.aad4225
57. Yamada T Yang Y Hemberg M Yoshida T Cho HY Murphy JP Promoter decommissioning by the NuRD chromatin remodeling complex triggers synaptic connectivity in the mammalian brain Neuron 2014 83 1 122 134 10.1016/j.neuron.2014.05.039 24991957
Yamada T, Yang Y, Hemberg M, Yoshida T, Cho HY, Murphy JP et al (2014) Promoter decommissioning by the NuRD chromatin remodeling complex triggers synaptic connectivity in the mammalian brain. Neuron 83(1):122–134. 10.1016/j.neuron.2014.05.03924991957 10.1016/j.neuron.2014.05.039
58. Needham EJ Parker BL Burykin T James DE Humphrey SJ Illuminating the dark phosphoproteome Sci Signal 2019 10.1126/scisignal.aau8645 30670635
Needham EJ, Parker BL, Burykin T, James DE, Humphrey SJ (2019) Illuminating the dark phosphoproteome. Sci Signal. 10.1126/scisignal.aau864530670635 10.1126/scisignal.aau8645
59. Bendris N Lemmers B Blanchard JM Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors Cell Cycle 2015 14 12 1786 1798 10.1080/15384101.2014.998085 25789852
Bendris N, Lemmers B, Blanchard JM (2015) Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors. Cell Cycle 14(12):1786–1798. 10.1080/15384101.2014.99808525789852 10.1080/15384101.2014.998085
60. Canning P Park K Goncalves J Li C Howard CJ Sharpe TD CDKL family kinases have evolved distinct structural features and ciliary function Cell Rep 2018 22 4 885 894 10.1016/j.celrep.2017.12.083 29420175
Canning P, Park K, Goncalves J, Li C, Howard CJ, Sharpe TD et al (2018) CDKL family kinases have evolved distinct structural features and ciliary function. Cell Rep 22(4):885–894. 10.1016/j.celrep.2017.12.08329420175 10.1016/j.celrep.2017.12.083
61. Angelo M Plattner F Giese KP Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory J Neurochem 2006 99 2 353 370 10.1111/j.1471-4159.2006.04040.x 17029592
Angelo M, Plattner F, Giese KP (2006) Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory. J Neurochem 99(2):353–370. 10.1111/j.1471-4159.2006.04040.x17029592 10.1111/j.1471-4159.2006.04040.x
62. Lucas JJ Hernandez F Gomez-Ramos P Moran MA Hen R Avila J Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice EMBO J 2001 20 1–2 27 39 10.1093/emboj/20.1.27 11226152
Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20(1–2):27–39. 10.1093/emboj/20.1.2711226152 10.1093/emboj/20.1.27
63. Trovo L Fuchs C De Rosa R Barbiero I Tramarin M Ciani E The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo Neurobiol Dis 2020 138 104791 10.1016/j.nbd.2020.104791 32032735
Trovo L, Fuchs C, De Rosa R, Barbiero I, Tramarin M, Ciani E et al (2020) The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo. Neurobiol Dis 138:104791. 10.1016/j.nbd.2020.10479132032735 10.1016/j.nbd.2020.104791
64. Seira O Del Rio JA Glycogen synthase kinase 3 beta (GSK3beta) at the tip of neuronal development and regeneration Mol Neurobiol 2014 49 2 931 944 10.1007/s12035-013-8571-y 24158777
Seira O, Del Rio JA (2014) Glycogen synthase kinase 3 beta (GSK3beta) at the tip of neuronal development and regeneration. Mol Neurobiol 49(2):931–944. 10.1007/s12035-013-8571-y24158777 10.1007/s12035-013-8571-y
65. Fuchs C Rimondini R Viggiano R Trazzi S De Franceschi M Bartesaghi R Inhibition of GSK3beta rescues hippocampal development and learning in a mouse model of CDKL5 disorder Neurobiol Dis 2015 82 298 310 10.1016/j.nbd.2015.06.018 26143616
Fuchs C, Rimondini R, Viggiano R, Trazzi S, De Franceschi M, Bartesaghi R et al (2015) Inhibition of GSK3beta rescues hippocampal development and learning in a mouse model of CDKL5 disorder. Neurobiol Dis 82:298–310. 10.1016/j.nbd.2015.06.01826143616 10.1016/j.nbd.2015.06.018
66. Fuchs C Fustini N Trazzi S Gennaccaro L Rimondini R Ciani E Treatment with the GSK3-beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice Eur J Neurosci 2018 47 9 1054 1066 10.1111/ejn.13923 29603837
Fuchs C, Fustini N, Trazzi S, Gennaccaro L, Rimondini R, Ciani E (2018) Treatment with the GSK3-beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice. Eur J Neurosci 47(9):1054–1066. 10.1111/ejn.1392329603837 10.1111/ejn.13923
67. Salcedo-Tello P Ortiz-Matamoros A Arias C GSK3 function in the brain during development, neuronal plasticity, and neurodegeneration Int J Alzheimers Dis 2011 2011 189728 10.4061/2011/189728 21660241
Salcedo-Tello P, Ortiz-Matamoros A, Arias C (2011) GSK3 function in the brain during development, neuronal plasticity, and neurodegeneration. Int J Alzheimers Dis 2011:189728. 10.4061/2011/18972821660241 10.4061/2011/189728
68. Negraes PD Trujillo CA Yu NK Wu W Yao H Liang N Altered network and rescue of human neurons derived from individuals with early-onset genetic epilepsy Mol Psychiatry 2021 26 11 7047 7068 10.1038/s41380-021-01104-2 33888873
Negraes PD, Trujillo CA, Yu NK, Wu W, Yao H, Liang N et al (2021) Altered network and rescue of human neurons derived from individuals with early-onset genetic epilepsy. Mol Psychiatry 26(11):7047–7068. 10.1038/s41380-021-01104-233888873 10.1038/s41380-021-01104-2
69. Ramkumar A Jong BY Ori-McKenney KM ReMAPping the microtubule landscape: how phosphorylation dictates the activities of microtubule-associated proteins Dev Dyn 2018 247 1 138 155 10.1002/dvdy.24599 28980356
Ramkumar A, Jong BY, Ori-McKenney KM (2018) ReMAPping the microtubule landscape: how phosphorylation dictates the activities of microtubule-associated proteins. Dev Dyn 247(1):138–155. 10.1002/dvdy.2459928980356 10.1002/dvdy.24599
70. Barbiero I De Rosa R Kilstrup-Nielsen C Microtubules: a key to understand and correct neuronal defects in CDKL5 deficiency disorder? Int J Mol Sci 2019 20 17 4075 10.3390/ijms20174075 31438497
Barbiero I, De Rosa R, Kilstrup-Nielsen C (2019) Microtubules: a key to understand and correct neuronal defects in CDKL5 deficiency disorder? Int J Mol Sci 20(17):4075. 10.3390/ijms2017407531438497 10.3390/ijms20174075
71. Barbiero I Valente D Chandola C Magi F Bergo A Monteonofrio L CDKL5 localizes at the centrosome and midbody and is required for faithful cell division Sci Rep 2017 7 1 1 12 10.1038/s41598-017-05875-z 28127051
Barbiero I, Valente D, Chandola C, Magi F, Bergo A, Monteonofrio L et al (2017) CDKL5 localizes at the centrosome and midbody and is required for faithful cell division. Sci Rep 7(1):1–1228127051 10.1038/s41598-017-05875-z
72. Barbiero I Peroni D Tramarin M Chandola C Rusconi L Landsberger N The neurosteroid pregnenolone reverts microtubule derangement induced by the loss of a functional CDKL5-IQGAP1 complex Hum Mol Genet 2017 26 18 3520 3530 10.1093/hmg/ddx237 28641386
Barbiero I, Peroni D, Tramarin M, Chandola C, Rusconi L, Landsberger N et al (2017) The neurosteroid pregnenolone reverts microtubule derangement induced by the loss of a functional CDKL5-IQGAP1 complex. Hum Mol Genet 26(18):3520–3530. 10.1093/hmg/ddx23728641386 10.1093/hmg/ddx237
73. Long Y Sou WH Yung KWY Liu H Wan SWC Li Q Distinct mechanisms govern the phosphorylation of different SR protein splicing factors J Biol Chem 2019 294 4 1312 1327 10.1074/jbc.RA118.003392 30478176
Long Y, Sou WH, Yung KWY, Liu H, Wan SWC, Li Q et al (2019) Distinct mechanisms govern the phosphorylation of different SR protein splicing factors. J Biol Chem 294(4):1312–1327. 10.1074/jbc.RA118.00339230478176 10.1074/jbc.RA118.003392
74. Ricciardi S Kilstrup-Nielsen C Bienvenu T Jacquette A Landsberger N Broccoli V CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery Hum Mol Genet 2009 18 23 4590 4602 10.1093/hmg/ddp426 19740913
Ricciardi S, Kilstrup-Nielsen C, Bienvenu T, Jacquette A, Landsberger N, Broccoli V (2009) CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery. Hum Mol Genet 18(23):4590–4602. 10.1093/hmg/ddp42619740913 10.1093/hmg/ddp426
75. Kameshita I Sekiguchi M Hamasaki D Sugiyama Y Hatano N Suetake I Cyclin-dependent kinase-like 5 binds and phosphorylates DNA methyltransferase 1 Biochem Biophys Res Commun 2008 377 4 1162 1167 10.1016/j.bbrc.2008.10.113 18977197
Kameshita I, Sekiguchi M, Hamasaki D, Sugiyama Y, Hatano N, Suetake I et al (2008) Cyclin-dependent kinase-like 5 binds and phosphorylates DNA methyltransferase 1. Biochem Biophys Res Commun 377(4):1162–1167. 10.1016/j.bbrc.2008.10.11318977197 10.1016/j.bbrc.2008.10.113
76. Kim JY Bai Y Jayne LA Hector RD Persaud AK Ong SS A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury Nat Commun 2020 11 1 1924 10.1038/s41467-020-15638-6 32317630
Kim JY, Bai Y, Jayne LA, Hector RD, Persaud AK, Ong SS et al (2020) A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury. Nat Commun 11(1):1924. 10.1038/s41467-020-15638-632317630 10.1038/s41467-020-15638-6
77. Fuchs C Medici G Trazzi S Gennaccaro L Galvani G Berteotti C CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling Brain Pathol 2019 29 5 658 674 10.1111/bpa.12716 30793413
Fuchs C, Medici G, Trazzi S, Gennaccaro L, Galvani G, Berteotti C et al (2019) CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling. Brain Pathol 29(5):658–674. 10.1111/bpa.1271630793413 10.1111/bpa.12716
78. Khanam T Munoz I Weiland F Carroll T Morgan M Borsos BN CDKL5 kinase controls transcription-coupled responses to DNA damage EMBO J 2021 40 23 e108271 10.15252/embj.2021108271 34605059
Khanam T, Munoz I, Weiland F, Carroll T, Morgan M, Borsos BN et al (2021) CDKL5 kinase controls transcription-coupled responses to DNA damage. EMBO J 40(23):e108271. 10.15252/embj.202110827134605059 10.15252/embj.2021108271
79. Fong CS Ozaki K Tsou MB PPP1R35 ensures centriole homeostasis by promoting centriole-to-centrosome conversion Mol Biol Cell 2018 29 23 2801 2808 10.1091/mbc.E18-08-0525 30230954
Fong CS, Ozaki K, Tsou MB (2018) PPP1R35 ensures centriole homeostasis by promoting centriole-to-centrosome conversion. Mol Biol Cell 29(23):2801–2808. 10.1091/mbc.E18-08-052530230954 10.1091/mbc.E18-08-0525
80. Archambault D Cheong A Iverson E Tremblay KD Mager J Protein phosphatase 1 regulatory subunit 35 is required for ciliogenesis, notochord morphogenesis, and cell-cycle progression during murine development Dev Biol 2020 465 1 1 10 10.1016/j.ydbio.2020.06.011 32628936
Archambault D, Cheong A, Iverson E, Tremblay KD, Mager J (2020) Protein phosphatase 1 regulatory subunit 35 is required for ciliogenesis, notochord morphogenesis, and cell-cycle progression during murine development. Dev Biol 465(1):1–10. 10.1016/j.ydbio.2020.06.01132628936 10.1016/j.ydbio.2020.06.011
81. Panda P Kovacs L Dzhindzhev N Fatalska A Persico V Geymonat M Tissue specific requirement of Drosophila Rcd4 for centriole duplication and ciliogenesis J Cell Biol 2020 10.1083/jcb.201912154 32543652
Panda P, Kovacs L, Dzhindzhev N, Fatalska A, Persico V, Geymonat M et al (2020) Tissue specific requirement of Drosophila Rcd4 for centriole duplication and ciliogenesis. J Cell Biol. 10.1083/jcb.20191215432543652 10.1083/jcb.201912154
82. Lepanto P Badano JL Zolessi FR Neuron's little helper: the role of primary cilia in neurogenesis Neurogenesis (Austin) 2016 3 1 e1253363 10.1080/23262133.2016.1253363 28090545
Lepanto P, Badano JL, Zolessi FR (2016) Neuron’s little helper: the role of primary cilia in neurogenesis. Neurogenesis (Austin) 3(1):e1253363. 10.1080/23262133.2016.125336328090545 10.1080/23262133.2016.1253363
83. Nigg EA Raff JW Centrioles, centrosomes, and cilia in health and disease Cell 2009 139 4 663 678 10.1016/j.cell.2009.10.036 19914163
Nigg EA, Raff JW (2009) Centrioles, centrosomes, and cilia in health and disease. Cell 139(4):663–678. 10.1016/j.cell.2009.10.03619914163 10.1016/j.cell.2009.10.036
84. Barbelanne M Tsang WY Molecular and cellular basis of autosomal recessive primary microcephaly Biomed Res Int 2014 2014 547986 10.1155/2014/547986 25548773
Barbelanne M, Tsang WY (2014) Molecular and cellular basis of autosomal recessive primary microcephaly. Biomed Res Int 2014:547986. 10.1155/2014/54798625548773 10.1155/2014/547986
85. Dawood M Akay G Mitani T Marafi D Fatih JM Gezdirici A A biallelic frameshift indel in PPP1R35 as a cause of primary microcephaly Am J Med Genet A 2023 191 3 794 804 10.1002/ajmg.a.63080 36598158
Dawood M, Akay G, Mitani T, Marafi D, Fatih JM, Gezdirici A et al (2023) A biallelic frameshift indel in PPP1R35 as a cause of primary microcephaly. Am J Med Genet A 191(3):794–804. 10.1002/ajmg.a.6308036598158 10.1002/ajmg.a.63080
86. Hu H Kahrizi K Musante L Fattahi Z Herwig R Hosseini M Genetics of intellectual disability in consanguineous families Mol Psychiatry 2019 24 7 1027 1039 10.1038/s41380-017-0012-2 29302074
Hu H, Kahrizi K, Musante L, Fattahi Z, Herwig R, Hosseini M et al (2019) Genetics of intellectual disability in consanguineous families. Mol Psychiatry 24(7):1027–1039. 10.1038/s41380-017-0012-229302074 10.1038/s41380-017-0012-2
87. Sydor AM Coyaud E Rovelli C Laurent E Liu H Raught B PPP1R35 is a novel centrosomal protein that regulates centriole length in concert with the microcephaly protein RTTN Elife 2018 10.7554/eLife.37846 30168418
Sydor AM, Coyaud E, Rovelli C, Laurent E, Liu H, Raught B et al (2018) PPP1R35 is a novel centrosomal protein that regulates centriole length in concert with the microcephaly protein RTTN. Elife. 10.7554/eLife.3784630168418 10.7554/eLife.37846
88. Graser S Stierhof YD Lavoie SB Gassner OS Lamla S Le Clech M Cep164, a novel centriole appendage protein required for primary cilium formation J Cell Biol 2007 179 2 321 330 10.1083/jcb.200707181 17954613
Graser S, Stierhof YD, Lavoie SB, Gassner OS, Lamla S, Le Clech M et al (2007) Cep164, a novel centriole appendage protein required for primary cilium formation. J Cell Biol 179(2):321–330. 10.1083/jcb.20070718117954613 10.1083/jcb.200707181
89. Vandervore LV Schot R Kasteleijn E Oegema R Stouffs K Gheldof A Heterogeneous clinical phenotypes and cerebral malformations reflected by rotatin cellular dynamics Brain 2019 142 4 867 884 10.1093/brain/awz045 30879067
Vandervore LV, Schot R, Kasteleijn E, Oegema R, Stouffs K, Gheldof A et al (2019) Heterogeneous clinical phenotypes and cerebral malformations reflected by rotatin cellular dynamics. Brain 142(4):867–884. 10.1093/brain/awz04530879067 10.1093/brain/awz045
90. Tam LW Ranum PT Lefebvre PA CDKL5 regulates flagellar length and localizes to the base of the flagella in Chlamydomonas Mol Biol Cell 2013 24 5 588 600 10.1091/mbc.E12-10-0718 23283985
Tam LW, Ranum PT, Lefebvre PA (2013) CDKL5 regulates flagellar length and localizes to the base of the flagella in Chlamydomonas. Mol Biol Cell 24(5):588–600. 10.1091/mbc.E12-10-071823283985 10.1091/mbc.E12-10-0718
91. Di Nardo A Ruhmkorf A Award P Brennecke A Fagiolini M Sahin M Phenotypic characterization of Cdkl5-knockdown neurons establishes elongated cilia as a functional assay for CDKL5 deficiency disorder Neurosci Res 2022 176 73 78 10.1016/j.neures.2021.10.001 34624412
Di Nardo A, Ruhmkorf A, Award P, Brennecke A, Fagiolini M, Sahin M (2022) Phenotypic characterization of Cdkl5-knockdown neurons establishes elongated cilia as a functional assay for CDKL5 deficiency disorder. Neurosci Res 176:73–78. 10.1016/j.neures.2021.10.00134624412 10.1016/j.neures.2021.10.001
92. Oi A Katayama S Hatano N Sugiyama Y Kameshita I Sueyoshi N Subcellular distribution of cyclin-dependent kinase-like 5 (CDKL5) is regulated through phosphorylation by dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) Biochem Biophys Res Commun 2017 482 2 239 245 10.1016/j.bbrc.2016.11.048 27840050
Oi A, Katayama S, Hatano N, Sugiyama Y, Kameshita I, Sueyoshi N (2017) Subcellular distribution of cyclin-dependent kinase-like 5 (CDKL5) is regulated through phosphorylation by dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). Biochem Biophys Res Commun 482(2):239–245. 10.1016/j.bbrc.2016.11.04827840050 10.1016/j.bbrc.2016.11.048
93. La Montanara P Rusconi L Locarno A Forti L Barbiero I Tramarin M Synaptic synthesis, dephosphorylation, and degradation: a novel paradigm for an activity-dependent neuronal control of CDKL5 J Biol Chem 2015 290 7 4512 4527 10.1074/jbc.M114.589762 25555910
La Montanara P, Rusconi L, Locarno A, Forti L, Barbiero I, Tramarin M et al (2015) Synaptic synthesis, dephosphorylation, and degradation: a novel paradigm for an activity-dependent neuronal control of CDKL5. J Biol Chem 290(7):4512–4527. 10.1074/jbc.M114.58976225555910 10.1074/jbc.M114.589762
94. Hendrickx A Beullens M Ceulemans H Den Abt T Van Eynde A Nicolaescu E Docking motif-guided mapping of the interactome of protein phosphatase-1 Chem Biol 2009 16 4 365 371 10.1016/j.chembiol.2009.02.012 19389623
Hendrickx A, Beullens M, Ceulemans H, Den Abt T, Van Eynde A, Nicolaescu E et al (2009) Docking motif-guided mapping of the interactome of protein phosphatase-1. Chem Biol 16(4):365–371. 10.1016/j.chembiol.2009.02.01219389623 10.1016/j.chembiol.2009.02.012
95. Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ, et al. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal. 2010;3(104):ra3. 10.1126/scisignal.2000475
96. Dephoure N Zhou C Villen J Beausoleil SA Bakalarski CE Elledge SJ A quantitative atlas of mitotic phosphorylation Proc Natl Acad Sci USA 2008 105 31 10762 10767 10.1073/pnas.0805139105 18669648
Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ et al (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci USA 105(31):10762–10767. 10.1073/pnas.080513910518669648 10.1073/pnas.0805139105
97. Chi Y Welcker M Hizli AA Posakony JJ Aebersold R Clurman BE Identification of CDK2 substrates in human cell lysates Genome Biol 2008 9 10 R149 10.1186/gb-2008-9-10-r149 18847512
Chi Y, Welcker M, Hizli AA, Posakony JJ, Aebersold R, Clurman BE (2008) Identification of CDK2 substrates in human cell lysates. Genome Biol 9(10):R149. 10.1186/gb-2008-9-10-r14918847512 10.1186/gb-2008-9-10-r149
98. Fardilha M Esteves SL Korrodi-Gregorio L Vintem AP Domingues SC Rebelo S Identification of the human testis protein phosphatase 1 interactome Biochem Pharmacol 2011 82 10 1403 1415 10.1016/j.bcp.2011.02.018 21382349
Fardilha M, Esteves SL, Korrodi-Gregorio L, Vintem AP, Domingues SC, Rebelo S et al (2011) Identification of the human testis protein phosphatase 1 interactome. Biochem Pharmacol 82(10):1403–1415. 10.1016/j.bcp.2011.02.01821382349 10.1016/j.bcp.2011.02.018
99. Kim DW Cochran BH Extracellular signal-regulated kinase binds to TFII-I and regulates its activation of the c-fos promoter Mol Cell Biol 2000 20 4 1140 1148 10.1128/mcb.20.4.1140-1148.2000 10648599
Kim DW, Cochran BH (2000) Extracellular signal-regulated kinase binds to TFII-I and regulates its activation of the c-fos promoter. Mol Cell Biol 20(4):1140–1148. 10.1128/mcb.20.4.1140-1148.200010648599 10.1128/mcb.20.4.1140-1148.2000
100. Danoff SK Taylor HE Blackshaw S Desiderio S TFII-I, a candidate gene for Williams syndrome cognitive profile: parallels between regional expression in mouse brain and human phenotype Neuroscience 2004 123 4 931 938 10.1016/j.neuroscience.2003.08.038 14751286
Danoff SK, Taylor HE, Blackshaw S, Desiderio S (2004) TFII-I, a candidate gene for Williams syndrome cognitive profile: parallels between regional expression in mouse brain and human phenotype. Neuroscience 123(4):931–938. 10.1016/j.neuroscience.2003.08.03814751286 10.1016/j.neuroscience.2003.08.038
101. Adams JW Vinokur A de Souza JS Austria C Guerra BS Herai RH Loss of GTF2I promotes neuronal apoptosis and synaptic reduction in human cellular models of neurodevelopment Cell Rep 2024 43 3 113867 10.1016/j.celrep.2024.113867 38416640
Adams JW, Vinokur A, de Souza JS, Austria C, Guerra BS, Herai RH et al (2024) Loss of GTF2I promotes neuronal apoptosis and synaptic reduction in human cellular models of neurodevelopment. Cell Rep 43(3):113867. 10.1016/j.celrep.2024.11386738416640 10.1016/j.celrep.2024.113867
102. Lopez-Tobon A Shyti R Villa CE Cheroni C Fuentes-Bravo P Trattaro S GTF2I dosage regulates neuronal differentiation and social behavior in 7q11.23 neurodevelopmental disorders Sci Adv 2023 9 48 eadh2726 10.1126/sciadv.adh2726 38019906
Lopez-Tobon A, Shyti R, Villa CE, Cheroni C, Fuentes-Bravo P, Trattaro S et al (2023) GTF2I dosage regulates neuronal differentiation and social behavior in 7q11.23 neurodevelopmental disorders. Sci Adv 9(48):eadh2726. 10.1126/sciadv.adh272638019906 10.1126/sciadv.adh2726
103. Barak B Feng G Neurobiology of social behavior abnormalities in autism and Williams syndrome Nat Neurosci 2016 19 6 647 655 10.1038/nn.4276 29323671
Barak B, Feng G (2016) Neurobiology of social behavior abnormalities in autism and Williams syndrome. Nat Neurosci 19(6):647–655. 10.1038/nn.427629323671 10.1038/nn.4276
104. Chimge NO Makeyev AV Ruddle FH Bayarsaihan D Identification of the TFII-I family target genes in the vertebrate genome Proc Natl Acad Sci USA 2008 105 26 9006 9010 10.1073/pnas.0803051105 18579769
Chimge NO, Makeyev AV, Ruddle FH, Bayarsaihan D (2008) Identification of the TFII-I family target genes in the vertebrate genome. Proc Natl Acad Sci USA 105(26):9006–9010. 10.1073/pnas.080305110518579769 10.1073/pnas.0803051105
105. Hakre S Tussie-Luna MI Ashworth T Novina CD Settleman J Sharp PA Opposing functions of TFII-I spliced isoforms in growth factor-induced gene expression Mol Cell 2006 24 2 301 308 10.1016/j.molcel.2006.09.005 17052463
Hakre S, Tussie-Luna MI, Ashworth T, Novina CD, Settleman J, Sharp PA et al (2006) Opposing functions of TFII-I spliced isoforms in growth factor-induced gene expression. Mol Cell 24(2):301–308. 10.1016/j.molcel.2006.09.00517052463 10.1016/j.molcel.2006.09.005
106. Smeyne RJ Vendrell M Hayward M Baker SJ Miao GG Schilling K Continuous c-fos expression precedes programmed cell death in vivo Nature 1993 363 6425 166 169 10.1038/363166a0 8483500
Smeyne RJ, Vendrell M, Hayward M, Baker SJ, Miao GG, Schilling K et al (1993) Continuous c-fos expression precedes programmed cell death in vivo. Nature 363(6425):166–169. 10.1038/363166a08483500 10.1038/363166a0
107. Zhang J Zhang D McQuade JS Behbehani M Tsien JZ Xu M c-fos regulates neuronal excitability and survival Nat Genet 2002 30 4 416 420 10.1038/ng859 11925568
Zhang J, Zhang D, McQuade JS, Behbehani M, Tsien JZ, Xu M (2002) c-fos regulates neuronal excitability and survival. Nat Genet 30(4):416–420. 10.1038/ng85911925568 10.1038/ng859
108. Pizzo R Gurgone A Castroflorio E Amendola E Gross C Sassoe-Pognetto M Lack of Cdkl5 disrupts the organization of excitatory and inhibitory synapses and parvalbumin interneurons in the primary visual cortex Front Cell Neurosci 2016 10 261 10.3389/fncel.2016.00261 27965538
Pizzo R, Gurgone A, Castroflorio E, Amendola E, Gross C, Sassoe-Pognetto M et al (2016) Lack of Cdkl5 disrupts the organization of excitatory and inhibitory synapses and parvalbumin interneurons in the primary visual cortex. Front Cell Neurosci 10:261. 10.3389/fncel.2016.0026127965538 10.3389/fncel.2016.00261
109. Pizzo R Lamarca A Sassoe-Pognetto M Giustetto M Structural bases of atypical whisker responses in a mouse model of CDKL5 deficiency disorder Neuroscience 2020 445 130 143 10.1016/j.neuroscience.2019.08.033 31472213
Pizzo R, Lamarca A, Sassoe-Pognetto M, Giustetto M (2020) Structural bases of atypical whisker responses in a mouse model of CDKL5 deficiency disorder. Neuroscience 445:130–143. 10.1016/j.neuroscience.2019.08.03331472213 10.1016/j.neuroscience.2019.08.033
110. Gennaccaro L Fuchs C Loi M Pizzo R Alvente S Berteotti C Age-related cognitive and motor decline in a mouse model of CDKL5 deficiency disorder is associated with increased neuronal senescence and death Aging Dis 2021 12 3 764 785 10.14336/AD.2020.0827 34094641
Gennaccaro L, Fuchs C, Loi M, Pizzo R, Alvente S, Berteotti C et al (2021) Age-related cognitive and motor decline in a mouse model of CDKL5 deficiency disorder is associated with increased neuronal senescence and death. Aging Dis 12(3):764–785. 10.14336/AD.2020.082734094641 10.14336/AD.2020.0827
111. Loi M Trazzi S Fuchs C Galvani G Medici G Gennaccaro L Increased DNA damage and apoptosis in CDKL5-deficient neurons Mol Neurobiol 2020 57 5 2244 2262 10.1007/s12035-020-01884-8 32002787
Loi M, Trazzi S, Fuchs C, Galvani G, Medici G, Gennaccaro L et al (2020) Increased DNA damage and apoptosis in CDKL5-deficient neurons. Mol Neurobiol 57(5):2244–2262. 10.1007/s12035-020-01884-832002787 10.1007/s12035-020-01884-8
112. Fan AX Papadopoulos GL Hossain MA Lin IJ Hu J Tang TM Genomic and proteomic analysis of transcription factor TFII-I reveals insight into the response to cellular stress Nucleic Acids Res 2014 42 12 7625 7641 10.1093/nar/gku467 24875474
Fan AX, Papadopoulos GL, Hossain MA, Lin IJ, Hu J, Tang TM et al (2014) Genomic and proteomic analysis of transcription factor TFII-I reveals insight into the response to cellular stress. Nucleic Acids Res 42(12):7625–7641. 10.1093/nar/gku46724875474 10.1093/nar/gku467
113. Chailangkarn T Noree C Muotri AR The contribution of GTF2I haploinsufficiency to Williams syndrome Mol Cell Probes 2018 40 45 51 10.1016/j.mcp.2017.12.005 29305905
Chailangkarn T, Noree C, Muotri AR (2018) The contribution of GTF2I haploinsufficiency to Williams syndrome. Mol Cell Probes 40:45–51. 10.1016/j.mcp.2017.12.00529305905 10.1016/j.mcp.2017.12.005
114. Kopp ND Nygaard KR McCullough KB Maloney SE Gabel HW Dougherty JD Functions of Gtf2i and Gtf2ird1 in the developing brain transcription DNA-binding, and long term behavioral consequences Human Mol Genet. 2019 10.1101/854851
Kopp ND, Nygaard KR, McCullough KB, Maloney SE, Gabel HW, Dougherty JD (2019) Functions of Gtf2i and Gtf2ird1 in the developing brain transcription DNA-binding, and long term behavioral consequences. Human Mol Genet. 10.1101/85485110.1101/854851
115. Malenfant P Liu X Hudson ML Qiao Y Hrynchak M Riendeau N Association of GTF2i in the Williams-Beuren syndrome critical region with autism spectrum disorders J Autism Dev Disord 2012 42 7 1459 1469 10.1007/s10803-011-1389-4 22048961
Malenfant P, Liu X, Hudson ML, Qiao Y, Hrynchak M, Riendeau N et al (2012) Association of GTF2i in the Williams-Beuren syndrome critical region with autism spectrum disorders. J Autism Dev Disord 42(7):1459–1469. 10.1007/s10803-011-1389-422048961 10.1007/s10803-011-1389-4
116. Deurloo MHS Turlova E Chen WL Lin YW Tam E Tassew NG Transcription factor 2I regulates neuronal development via TRPC3 in 7q1123 disorder models Mol Neurobiol 2019 56 5 3313 3325 10.1007/s12035-018-1290-7 30120731
Deurloo MHS, Turlova E, Chen WL, Lin YW, Tam E, Tassew NG et al (2019) Transcription factor 2I regulates neuronal development via TRPC3 in 7q1123 disorder models. Mol Neurobiol 56(5):3313–3325. 10.1007/s12035-018-1290-730120731 10.1007/s12035-018-1290-7
117. Tudor M Akbarian S Chen RZ Jaenisch R Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain Proc Natl Acad Sci USA 2002 99 24 15536 15541 10.1073/pnas.242566899 12432090
Tudor M, Akbarian S, Chen RZ, Jaenisch R (2002) Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc Natl Acad Sci USA 99(24):15536–15541. 10.1073/pnas.24256689912432090 10.1073/pnas.242566899
118. Chahrour M Jung SY Shaw C Zhou X Wong ST Qin J MeCP2, a key contributor to neurological disease, activates and represses transcription Science 2008 320 5880 1224 1229 10.1126/science.1153252 18511691
Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J et al (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320(5880):1224–1229. 10.1126/science.115325218511691 10.1126/science.1153252
119. Guy J Hendrich B Holmes M Martin JE Bird A A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome Nat Genet 2001 27 3 322 326 10.1038/85899 11242117
Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 27(3):322–326. 10.1038/8589911242117 10.1038/85899
120. Dai Q Ren A Westholm JO Serganov AA Patel DJ Lai EC The BEN domain is a novel sequence-specific DNA-binding domain conserved in neural transcriptional repressors Genes Dev 2013 27 6 602 614 10.1101/gad.213314.113 23468431
Dai Q, Ren A, Westholm JO, Serganov AA, Patel DJ, Lai EC (2013) The BEN domain is a novel sequence-specific DNA-binding domain conserved in neural transcriptional repressors. Genes Dev 27(6):602–614. 10.1101/gad.213314.11323468431 10.1101/gad.213314.113
121. Kara B Uyguner O Maras Genc H Islek EE Kasap M Toksoy G BEND4 as a candidate gene for an infection-induced acute encephalopathy characterized by a cyst and calcification of the pons and cerebellar atrophy Mol Syndromol 2022 13 1 12 22 10.1159/000517541 35221871
Kara B, Uyguner O, Maras Genc H, Islek EE, Kasap M, Toksoy G et al (2022) BEND4 as a candidate gene for an infection-induced acute encephalopathy characterized by a cyst and calcification of the pons and cerebellar atrophy. Mol Syndromol 13(1):12–22. 10.1159/00051754135221871 10.1159/000517541
122. Moriya H Quantitative nature of overexpression experiments Mol Biol Cell 2015 26 22 3932 3939 10.1091/mbc.E15-07-0512 26543202
Moriya H (2015) Quantitative nature of overexpression experiments. Mol Biol Cell 26(22):3932–3939. 10.1091/mbc.E15-07-051226543202 10.1091/mbc.E15-07-0512
123. Hoffmann A Spengler D Chromatin remodeling complex NuRD in neurodevelopment and neurodevelopmental disorders Front Genet 2019 10 682 10.3389/fgene.2019.00682 31396263
Hoffmann A, Spengler D (2019) Chromatin remodeling complex NuRD in neurodevelopment and neurodevelopmental disorders. Front Genet 10:682. 10.3389/fgene.2019.0068231396263 10.3389/fgene.2019.00682
124. Boulasiki P Tan XW Spinelli M Riccio A The NuRD complex in neurodevelopment and disease: a case of sliding doors Cells 2023 10.3390/cells12081179 37190088
Boulasiki P, Tan XW, Spinelli M, Riccio A (2023) The NuRD complex in neurodevelopment and disease: a case of sliding doors. Cells. 10.3390/cells1208117937190088 10.3390/cells12081179
125. Spruijt CG Grawe C Kleinendorst SC Baltissen MPA Vermeulen M Cross-linking mass spectrometry reveals the structural topology of peripheral NuRD subunits relative to the core complex FEBS J 2021 288 10 3231 3245 10.1111/febs.15650 33283408
Spruijt CG, Grawe C, Kleinendorst SC, Baltissen MPA, Vermeulen M (2021) Cross-linking mass spectrometry reveals the structural topology of peripheral NuRD subunits relative to the core complex. FEBS J 288(10):3231–3245. 10.1111/febs.1565033283408 10.1111/febs.15650
126. Spruijt CG Luijsterburg MS Menafra R Lindeboom RG Jansen PW Edupuganti RR ZMYND8 Co-localizes with NuRD on target genes and regulates poly(ADP-ribose)-dependent recruitment of GATAD2A/NuRD to sites of DNA damage Cell Rep 2016 17 3 783 798 10.1016/j.celrep.2016.09.037 27732854
Spruijt CG, Luijsterburg MS, Menafra R, Lindeboom RG, Jansen PW, Edupuganti RR et al (2016) ZMYND8 Co-localizes with NuRD on target genes and regulates poly(ADP-ribose)-dependent recruitment of GATAD2A/NuRD to sites of DNA damage. Cell Rep 17(3):783–798. 10.1016/j.celrep.2016.09.03727732854 10.1016/j.celrep.2016.09.037
127. Sharifi Tabar M Mackay JP Low JKK The stoichiometry and interactome of the nucleosome remodeling and deacetylase (NuRD) complex are conserved across multiple cell lines FEBS J 2019 286 11 2043 2061 10.1111/febs.14800 30828972
Sharifi Tabar M, Mackay JP, Low JKK (2019) The stoichiometry and interactome of the nucleosome remodeling and deacetylase (NuRD) complex are conserved across multiple cell lines. FEBS J 286(11):2043–2061. 10.1111/febs.1480030828972 10.1111/febs.14800
128. Ding X Liu S Tian M Zhang W Zhu T Li D Activity-induced histone modifications govern Neurexin-1 mRNA splicing and memory preservation Nat Neurosci 2017 20 5 690 699 10.1038/nn.4536 28346453
Ding X, Liu S, Tian M, Zhang W, Zhu T, Li D et al (2017) Activity-induced histone modifications govern Neurexin-1 mRNA splicing and memory preservation. Nat Neurosci 20(5):690–699. 10.1038/nn.453628346453 10.1038/nn.4536
129. Nitarska J Smith JG Sherlock WT Hillege MM Nott A Barshop WD A functional switch of NuRD chromatin remodeling complex subunits regulates mouse cortical development Cell Rep 2016 17 6 1683 1698 10.1016/j.celrep.2016.10.022 27806305
Nitarska J, Smith JG, Sherlock WT, Hillege MM, Nott A, Barshop WD et al (2016) A functional switch of NuRD chromatin remodeling complex subunits regulates mouse cortical development. Cell Rep 17(6):1683–1698. 10.1016/j.celrep.2016.10.02227806305 10.1016/j.celrep.2016.10.022
130. Torrado M Low JKK Silva APG Schmidberger JW Sana M Sharifi Tabar M Refinement of the subunit interaction network within the nucleosome remodelling and deacetylase (NuRD) complex FEBS J 2017 284 24 4216 4232 10.1111/febs.14301 29063705
Torrado M, Low JKK, Silva APG, Schmidberger JW, Sana M, Sharifi Tabar M et al (2017) Refinement of the subunit interaction network within the nucleosome remodelling and deacetylase (NuRD) complex. FEBS J 284(24):4216–4232. 10.1111/febs.1430129063705 10.1111/febs.14301
